,title,abstract,authors,link,ID,publication_date,update_date,subject,is_medRxiv
0,Aeromedical retrieval diagnostic trends during a period of Coronavirus 2019 lockdown,"Background: We aimed to compare the pre, lockdown, and post-lockdown aeromedical retrieval (AR) diagnostic reasons and patient demographics during a period of Coronavirus 2019 (COVID-19) social isolation. Methods: An observational study with retrospective data collection, consisting of Australians who received an AR between the 26 January to the 23 June 2020. The main outcome measures were patient diagnostic category proportions and trends prior (28 January to 15 March), during (16 March to 4 May), and following (5 May to 23 June 2020) social isolation restrictions. Results: There were 16981 ARs consisting of 1959 (11.5) primary evacuations (PE) and 12724 (88.5) inter-hospital transfer (IHT), with a population median age of 52 years old (interquartile range [IQR] 29.0 69.0), with 49.0% (n= 8283) of the cohort being male and 38.0% (n= 6399) being female. There were a total of 6 confirmed and 209 suspected cases of COVID-19, with the majority of cases (n=114; 53.0%) in the social isolation period. As compared to pre-restriction, the odds of retrieval for the restriction and post-restriction period differed across time between the major diagnostic groups. This included, an increase in cardiovascular retrieval for both restriction and post-restriction periods (OR 1.12 95% CI 1.02 1.24 and OR 1.18 95% CI 1.08 1.30 respectively), increases in neoplasm in the post restriction period (OR 1.31 95% CI 1.04 1.64), and increases for congenital conditions in the restriction period (OR 2.56 95% CI 1.39 4.71). Cardiovascular and congenital conditions had increased rates of priority 1 patients in the restriction and post restriction periods. There was a decrease in endocrine and metabolic disease retrievals in the restriction period (OR 0.72 95% CI 0.53 0.98). There were lower odds during the post-restriction period for a retrievals of the respiratory system (OR 0.78 95% CI 0.67 0.93), and disease of the skin (OR 0.78 95% CI 0.6 1.0). Distribution between the 2019 and 2020 time periods differed (p<0.05), with the lockdown period resulting in a significant reduction in activity. Conclusion: The lockdown period resulted in increased AR rates of circulatory and congenital conditions. However, this period also resulted in a reduction of overall activity, possibly due to a reduction in other infectious disease rates, such as influenza, due to social distancing.","Gardiner, F. W.; Gillam, M.; Churilov, L.; Sharma, P.; Steere, M.; Hanna, M.; Hooper, A.; Quinlan, F.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176230v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176230v1?rss=1,2020-08-19,2020-08-19,,True
1,Boosting SARS-CoV-2 qRT-PCR detection combining pool sample strategy and mathematical modeling,"qRT-PCR is the gold standard technique available for SARS-CoV-2 detection. However, the long test run time and costs associated with this type of molecular testing are a challenge in the actual pandemic scenario. Due to high testing demand, pooling sample strategy is an interesting approach to allow cost savings. We aim to evaluate pooling tests in experimental procedures, as well as perform in silico statistical modeling analysis validated with specimen samples obtained from a mass testing program of Industry Federation of the State of Rio de Janeiro (Brazil). Although the sensitivity reduction in samples pooled with 32 individuals was observed, the high-test sensitivity is maintained even when 16 and 8 samples were pooled. The in silico analysis showed high-cost savings in populations with positive rates lower than 15.0% according to the pool size. This data was validated with the results obtained in our mass testing program: statistical modeling predicted a cost saving of 48.0%, which in practice, was 51.5%, already considering the expenditures with pool sampling that were analyzed individually. Our data confirmed that mathematical modeling is a powerful strategy to improve the pooling approach for SARS-CoV-2 mass testing around the world while maintaining high sensitivity and robustness.","Correa, I. A.; Rodrigues, T. d. S.; Queiroz, A.; Nascimento, L. d. F.; Wolff, T.; Akamine, R. N.; Kuriyama, S. N.; Costa, L.; Fidalgo-Neto, A. A.","https://www.medrxiv.org/content/10.1101/2020.08.16.20167536v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20167536v1?rss=1,2020-08-19,2020-08-19,,True
2,Information given by websites selling home self-sampling COVID-19 tests: An analysis of accuracy and completeness,"Objectives: To assess the accuracy and completeness of information provided by websites selling home self-sampling and testing kits for COVID-19. Design: Cross-sectional observational study. Setting: All websites (n=27) selling direct to user home self-sampling and testing for COVID-19 (41 tests) in the UK (39 tests) and US (2 tests) identified by a website search on 23rd May 2020. Main outcome measures: Thirteen predefined basic information items to communicate to a user, including who should be tested, when and how testing should be done, test accuracy, and interpretation of results. Results: Many websites did not provide the name or manufacturer of the test (32/41; 78%), when to use the test (10/41; 24%), test accuracy (12/41; 29%), and how to interpret results (21/41; 51%). Sensitivity and specificity were the most commonly reported test accuracy measures (either reported for 27/41 (66%) tests); we could only link these figures to manufacturers documents or publications for four (10%) tests. Predictive values, most relevant to users, were rarely reported (five [12%] tests reported positive predictive values). For molecular virus tests, 9/23 (39%) websites explained that test positives should self-isolate, and 8/23 (35%) explained that test negatives may still have the disease. For antibody tests, 12/18 (67%) websites explained that testing positive does not necessarily infer immunity from future infection. Seven (39%) websites selling antibody tests claimed the test had a CE mark, when they were for a different intended use (venous blood rather than finger-prick samples). Conclusions: At the point of online purchase of home self-sampling COVID-19 tests, users in the UK are provided with incomplete, and in some cases misleading information on test accuracy, intended use and test interpretation. Best practice guidance for communication about tests to the public should be developed and enforced for online sales of COVID-19 tests.","Taylor-Phillips, S.; Berhane, S.; Sitch, A.; Freeman, K.; Price, M.; Davenport, C.; Geppert, J.; Harris, I.; Osokogu, O.; Skrybant, M.; Deeks, J. J.","https://www.medrxiv.org/content/10.1101/2020.08.18.20177360v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.18.20177360v1?rss=1,2020-08-19,2020-08-19,,True
3,Effects of case- and population-based COVID-19 interventions in Taiwan,"In the first wave of the COVID-19 pandemic, broad usage of non-pharmaceutical interventions played a crucial role in controlling epidemics. However, the substantial economic and societal costs of continuous use of border controls, travel restrictions, and physical distancing measures suggest that these measures may not be sustainable and that policymakers have to seek strategies to lift the restrictions. Taiwan was one of the few countries that demonstrated initial success in eliminating the COVID-19 outbreak without strict lockdown or school closure. To understand the key contributors to the successful control, we applied a stochastic branching model to empirical case data to evaluate and compare the effectiveness of more targeted case-based (including contact tracing and quarantine) and less targeted population-based interventions (including social distancing and face mask use) in Taiwan. We found that case-based interventions alone would not be sufficient to contain the epidemic, even in a setting where a highly efficient contact tracing program was in place. The voluntary population-based interventions have reduced the reproduction numbers by more than 60% and have likely played a critical role at the early stage of the outbreak. Our analysis of Taiwan's success highlights that coordinated efforts from both the government and the citizens are indispensable in the fight against COVID-19 pandemic.","Ng, T.-C. V.; Cheng, H.-Y.; Chang, H.-H.; Liu, C.-C.; Yang, C.-C.; Jian, S.-W.; Liu, D.-P.; Cohen, T.; Lin, H.-H.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176255v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176255v1?rss=1,2020-08-19,2020-08-19,,True
4,Multi-organ Proteomic Landscape of COVID-19 Autopsies,"The molecular pathology of multi-organ injuries in COVID-19 patients remains unclear, preventing effective therapeutics development. Here, we report an in-depth multi-organ proteomic landscape of COVID-19 patient autopsy samples. By integrative analysis of proteomes of seven organs, namely lung, spleen, liver, heart, kidney, thyroid and testis, we characterized 11,394 proteins, in which 5336 were perturbed in COVID-19 patients compared to controls. Our data showed that CTSL, rather than ACE2, was significantly upregulated in the lung from COVID-19 patients. Dysregulation of protein translation, glucose metabolism, fatty acid metabolism was detected in multiple organs. Our data suggested upon SARS-CoV-2 infection, hyperinflammation might be triggered which in turn induces damage of gas exchange barrier in the lung, leading to hypoxia, angiogenesis, coagulation and fibrosis in the lung, kidney, spleen, liver, heart and thyroid. Evidence for testicular injuries included reduced Leydig cells, suppressed cholesterol biosynthesis and sperm mobility. In summary, this study depicts the multi-organ proteomic landscape of COVID-19 autopsies, and uncovered dysregulated proteins and biological processes, offering novel therapeutic clues.","Xiu, N.; Qian, L.; Sun, R.; Huang, B.; Dong, X.; Xiao, Q.; Zhang, Q.; Lu, T.; Yue, L.; Chen, S.; Li, X.; Sun, Y.; Lu, L.; Xu, L.; Yan, L.; Yang, M.; Xue, Z.; Liang, S.; Ding, X.; Yuan, C.; Peng, L.; Liu, W.; Yi, X.; Lyu, M.; Xiao, G.; Xu, X.; Ge, W.; He, J.; Fan, J.; Wu, J.; Luo, M.; Chang, X.; Pan, H.; Cai, X.; Zhou, J.; Yu, J.; Gao, H.; Xie, M.; Wang, S.; Ruan, G.; Chen, H.; Su, H.; Mei, H.; Luo, D.; Zhao, D.; Xu, F.; Li, Y.; Zhu, Y.; Xia, J.; Hu, Y.; Guo, T.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176065v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176065v1?rss=1,2020-08-19,2020-08-19,,True
5,The necessary cooperation between governments and public in the fight against COVID-19: why non-pharmaceutical interventions may be ineffective,"The coronavirus disease (COVID-19) outbreak is the biggest public health challenge in the last 100 years. No successful pharmaceutical treatment is yet available, thus effective public health interventions to contain COVID-19 include social distancing, isolation and quarantine measures. However the efficiency of these containment measures varied among countries and even within states in the same country. Despite Brazil being deeply affected by coronavirus, the federal government never proposed a coordinated action to control COVID-19 and Brazilian states, which are autonomous, each imposed different containment measures. The state of Goias declared strict social distancing measures in March 13, but gradually relaxed many of its first measures due specially to public pressure. Here we use a Susceptible-Infected-Recovered (SIR) model combined with Bayesian inference and a time-dependent spreading rate to assess how past state-level interventions affected the spread of COVID-19 in Goias. The interventions succeeded in decreasing the transmission rate in the state, however, after the third intervention the rate remained positive and exponential. Thus, other stricter interventions were made necessary to avoid the growth of new cases and a collapse in the health system. Governmental interventions need to be taken seriously by the population in order for them have the proposed outcome. Our results reflect the population's disregard with the measures imposed and the need for cooperation between governments and its citizens in the fight against COVID-19.","Borges, C. M.; Coelho, M. T. P.; Diniz-Filho, J. A. F.; Rangel, T. F.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176347v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176347v1?rss=1,2020-08-19,2020-08-19,,True
6,Suboptimal SARS-CoV-2-specific CD8+ T-cell response associated with the prominent HLA-A*02:01 phenotype,"An improved understanding of human T-cell-mediated immunity in COVID-19 is important if we are to optimize therapeutic and vaccine strategies. Experience with influenza shows that infection primes CD8+ T-cell memory to shared peptides presented by common HLA types like HLA-A2. Following re-infection, cross-reactive CD8+ T-cells enhance recovery and diminish clinical severity. Stimulating peripheral blood mononuclear cells from COVID-19 convalescent patients with overlapping peptides from SARS-CoV-2 Spike, Nucleocapsid and Membrane proteins led to the clonal expansion of SARS-CoV-2-specific CD8+ and CD4+ T-cells in vitro, with CD4+ sets being typically robust. For CD8+ T-cells taken directly ex vivo, we identified two HLA-A*02:01-restricted SARS-CoV-2 epitopes, A2/S269-277 and A2/Orf1ab3183-3191. Using peptide-HLA tetramer enrichment, direct ex vivo assessment of the A2/S269+CD8+ and A2/Orf1ab3183+CD8+ populations indicated that the more prominent A2/S269+CD8+ set was detected at comparable frequency (1.3x10-5) in acute and convalescent HLA-A*02:01+ patients. But, while the numbers were higher than those found in uninfected HLA-A*02:01+ donors (2.5x10-6), they were low when compared with frequencies for influenza-specific (A2/M158) and EBV-specific (A2/BMLF1280) (1.38x10-4) populations. Phenotypic analysis ex vivo of A2/S269+CD8+ T-cells from COVID-19 convalescents showed that A2/S269+CD8+ T-cells were predominantly negative for the CD38, HLA-DR, PD-1 and CD71 activation markers, although the majority of total CD8+ T-cells were granzyme and/or perforin-positive. Furthermore, the bias towards naive, stem cell memory and central memory A2/S269+CD8+ T-cells rather than effector memory populations suggests that SARS-CoV2 infection may be compromising CD8+ T-cell activation. Priming with an appropriate vaccine may thus have great value for optimizing protective CD8+ T-cell immunity in COVID-19.","Habel, J. R.; Nguyen, T. H. O.; van de Sandt, C. E.; Juno, J. A.; Chaurasia, P.; Wragg, K.; Koutsakos, M.; Hensen, L.; Chua, B.; Zhang, W.; Tan, H. X.; Flanagan, K. L.; Doolan, D.; Torresi, J.; Chen, W.; Wakim, L.; Cheng, A.; Petersen, J.; Rossjohn, J.; Wheatley, A. K.; Kent, S.; Rowntree, L.; Kedzierska, K.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176370v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176370v1?rss=1,2020-08-19,2020-08-19,,True
7,"Knowledge and Perception of COVID-19, Prevalence of Pre-Existing Conditions, and Access to Essential Resources and Health Services in Somali IDP Camps","Background: Three million internally displaced Somalis live in overcrowded settlements with weakened infrastructure, insufficient access to WASH facilities, and inaccessible health services. This vulnerable population is especially susceptible to COVID-19, which is expected to have worsened health outcomes and exacerbate existing structural challenges in the implementation of public health measures. This study examines knowledge of COVID-19, self-reported prevalence of preexisting conditions, and access to essential health services among residents of internally displaced persons (IDP) camps in Somalia. Methods: A descriptive, cross-sectional survey design assessing demographics, current health profiles, knowledge and perceptions of COVID-19, and access to resources was used. 401 Somali IDP camp residents completed the survey. Results: Though 77% of respondents reported taking at least one COVID-19 preventative public health measure, respondents reported a severe lack of access to adequate sanitation, an inability to practice social distancing, and nearly universal inability to receive a COVID-19 screening exam. Questions assessing knowledge surrounding COVID-19 prevention and treatment yielded answers of ""I don't know"" for roughly 50% of responses. The majority were not familiar with basic information about the virus or confident that they could receive medical services if infected. Those who perceived their health status to be ""fair,"" as opposed to ""good,"" showed 5.69 times higher odds of being concerned about contracting COVID-19. Respondents who felt more anxious or nervous and those who introduced one behavioral change to protect against COVID-19 transmission showed 10.16 and 5.20 times increased odds of being concerned about disease contraction, respectively. Conclusion: This study highlights immense gaps in the knowledge and perceptions of COVID-19 and access to treatment and preventative services among individuals living in Somali IDP camps. A massive influx of additional resources is required to adequately address COVID-19 in Somalia, starting with educating those individuals most vulnerable to infection.","Alawa, J.; Walz, L. A.; Al-Ali, S.; Wiles, E.; Harle, N.; Abdullahi, A. M.; Mohamed, D.; Khoshnood, K.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176271v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176271v1?rss=1,2020-08-19,2020-08-19,,True
8,"SARS-CoV-2 (COVID-19) infection in pregnant women: characterization of symptoms and syndromes predictive of disease and severity through real-time, remote participatory epidemiology.","Background: From the beginning of COVID-19 pandemic, pregnant women have been considered at greater risk of severe morbidity and mortality. However, data on hospitalized pregnant women show that the symptom profile and risk factors for severe disease are similar to those among women who are not pregnant, although preterm birth, Cesarean delivery, and stillbirth may be more frequent and vertical transmission is possible. Limited data are available for the cohort of pregnant women that gave rise to these hospitalized cases, hindering our ability to quantify risk of COVID-19 sequelae for pregnant women in the community. Objective: To test the hypothesis that pregnant women in community differ in their COVID-19 symptoms profile and disease severity compared to non-pregnant women. This was assessed in two community-based cohorts of women aged 18-44 years in the United Kingdom, Sweden and the United States of America. Study design: This observational study used prospectively collected longitudinal (smartphone application interface) and cross-sectional (web-based survey) data. Participants in the discovery cohort were drawn from 400,750 UK, Sweden and US women (79 pregnant who tested positive) who self-reported symptoms and events longitudinally via their smartphone, and a replication cohort drawn from 1,344,966 USA women (162 pregnant who tested positive) cross-sectional self-reports samples from the social media active user base. The study compared frequencies of symptoms and events, including self-reported SARS-CoV-2 testing and differences between pregnant and non-pregnant women who were hospitalized and those who recovered in the community. Multivariable regression was used to investigate disease severity and comorbidity effects. Results: Pregnant and non-pregnant women positive for SARS-CoV-2 infection drawn from these community cohorts were not different with respect to COVID-19-related severity. Pregnant women were more likely to have received SARS-CoV-2 testing than non-pregnant, despite reporting fewer clinical symptoms. Pre-existing lung disease was most closely associated with the severity of symptoms in pregnant hospitalized women. Heart and kidney diseases and diabetes were additional factors of increased risk. The most frequent symptoms among all non-hospitalized women were anosmia [63% in pregnant, 92% in non-pregnant] and headache [72%, 62%]. Cardiopulmonary symptoms, including persistent cough [80%] and chest pain [73%], were more frequent among pregnant women who were hospitalized. Gastrointestinal symptoms, including nausea and vomiting, were different among pregnant and non-pregnant women who developed severe outcomes. Conclusions: Although pregnancy is widely considered a risk factor for SARS-CoV-2 infection and outcomes, and was associated with higher propensity for testing, the profile of symptom characteristics and severity in our community-based cohorts were comparable to those observed among non-pregnant women, except for the gastrointestinal symptoms. Consistent with observations in non-pregnant populations, comorbidities such as lung disease and diabetes were associated with an increased risk of more severe SARS-CoV-2 infection during pregnancy. Pregnant women with pre-existing conditions require careful monitoring for the evolution of their symptoms during SARS-CoV-2 infection.","Molteni, E.; Astley, C. M.; Ma, W.; Sudre, C. H.; Magee, L. A.; Murray, B.; Fall, T.; Gomez, M. F.; Tsereteli, N.; Franks, P. W.; Brownstein, J. S.; Davies, R.; Wolf, J.; Spector, T.; Ourselin, S.; Steves, C.; Chan, A. T.; Modat, M.","https://www.medrxiv.org/content/10.1101/2020.08.17.20161760v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20161760v1?rss=1,2020-08-19,2020-08-19,,True
9,Bacterial modification of the host glycosaminoglycan heparan sulfate modulates SARS-CoV-2 infectivity,"The human microbiota has a close relationship with human disease and it remodels components of the glycocalyx including heparan sulfate (HS). Studies of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) spike protein receptor binding domain suggest that infection requires binding to HS and angiotensin converting enzyme 2 (ACE2) in a codependent manner. Here, we show that commensal host bacterial communities can modify HS and thereby modulate SARS-CoV-2 spike protein binding and that these communities change with host age and sex. Common human-associated commensal bacteria whose genomes encode HS-modifying enzymes were identified. The prevalence of these bacteria and the expression of key microbial glycosidases in bronchoalveolar lavage fluid (BALF) was lower in adult COVID-19 patients than in healthy controls. The presence of HS-modifying bacteria decreased with age in two large survey datasets, FINRISK 2002 and American Gut, revealing one possible mechanism for the observed increase in COVID-19 susceptibility with age. In vitro, bacterial glycosidases from unpurified culture media supernatants fully blocked SARS-CoV-2 spike binding to human H1299 protein lung adenocarcinoma cells. HS-modifying bacteria in human microbial communities may regulate viral adhesion, and loss of these commensals could predispose individuals to infection. Understanding the impact of shifts in microbial community composition and bacterial lyases on SARS-CoV-2 infection may lead to new therapeutics and diagnosis of susceptibility.","Martino, C.; Kellman, B. P.; Sandoval, D. R.; Clausen, T. M.; Marotz, C. A.; Song, S. J.; Wandro, S.; Zaramela, L. S.; Salido Benitez, R. A.; Zhu, Q.; Armingol, E.; Vazquez-Baeza, Y.; McDonald, D.; Sorrentino, J. T.; Taylor, B.; Belda-Ferre, P.; Liang, C.; Zhang, Y.; Schifanella, L.; Klatt, N. R.; Havulinna, A. S.; Jousilahti, P.; Huang, S.; Haiminen, N.; Parida, L.; Kim, H.-C.; Swafford, A. D.; Zengler, K.; Cheng, S.; Inouye, M.; Niiranen, T.; Jain, M.; Salomaa, V.; Esko, J. D.; Lewis, N. E.; Knight, R.","https://www.biorxiv.org/content/10.1101/2020.08.17.238444v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.238444v1?rss=1,2020-08-18,2020-08-18,,False
10,Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2,"Drug repurposing is a rapid approach to identifying therapeutics for the treatment of emerging infectious diseases such as COVID-19. To address the urgent need for treatment options, we carried out a quantitative high-throughput screen using a SARS-CoV-2 cytopathic assay with a compound collection of 8,810 approved and investigational drugs, mechanism-based bioactive compounds, and natural products. Three hundred and nineteen compounds with anti-SARS-CoV-2 activities were identified and confirmed, including 91 approved drug and 49 investigational drugs. Among these confirmed compounds, the anti-SARS-CoV-2 activities of 230 compounds, including 38 approved drugs, have not been previously reported. Chlorprothixene, methotrimeprazine, and piperacetazine were the three most potent FDA approved drugs with anti-SARS-CoV-2 activities. These three compounds have not been previously reported to have anti-SARS-CoV-2 activities, although their antiviral activities against SARS-CoV and Ebola virus have been reported. These results demonstrate that this comprehensive data set of drug repurposing screen for SARS-CoV-2 is useful for drug repurposing efforts including design of new drug combinations for clinical trials.","Chen, C. Z.; Shinn, P.; Itkin, Z.; Eastman, R.; Bostwick, R.; Rasmussen, L.; Huang, R.; Shen, M.; Hu, X.; Wilson, K. M.; Brooks, B.; Guo, H.; Zhao, T.; Klumpp-Thomas, C.; Simeonov, A.; Michael, S. G.; Lo, D. C.; Hall, M.; Zheng, W.","https://www.biorxiv.org/content/10.1101/2020.08.18.255877v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255877v1?rss=1,2020-08-18,2020-08-18,,False
11,KG-COVID-19: a framework to produce customized knowledge graphs for COVID-19 response,"Integrated, up-to-date data about SARS-CoV-2 and coronavirus disease 2019 (COVID-19) is crucial for the ongoing response to the COVID-19 pandemic by the biomedical research community. While rich biological knowledge exists for SARS-CoV-2 and related viruses (SARS-CoV, MERS-CoV), integrating this knowledge is difficult and time consuming, since much of it is in siloed databases or in textual format. Furthermore, the data required by the research community varies drastically for different tasks - the optimal data for a machine learning task, for example, is much different from the data used to populate a browsable user interface for clinicians. To address these challenges, we created KG-COVID-19, a flexible framework that ingests and integrates biomedical data to produce knowledge graphs (KGs) for COVID-19 response. This KG framework can also be applied to other problems in which siloed biomedical data must be quickly integrated for different research applications, including future pandemics.","Reese, J. T.; Unni, D. R.; Callahan, T. J.; Cappelletti, L.; Ravanmehr, V.; Carbon, S.; Fontana, T.; Blau, H.; Matentzoglu, N.; Harris, N. L.; Munoz-Torres, M. C.; Robinson, P. N.; Joachimiak, M. P.; Mungall, C. J.","https://www.biorxiv.org/content/10.1101/2020.08.17.254839v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.254839v1?rss=1,2020-08-18,2020-08-18,,False
12,Equine hyperimmune globulin raised against the SARS-CoV-2 spike glycoprotein has extremely high neutralizing titers,"COVID-19 pandemic caused approximately 750,000 deaths and over 20 million confirmed cases of infection by SARS-CoV-2 within 8 months since the emergence of the virus. While there are no vaccines approved and considering the difficulty in meeting the large vaccination demand worldwide, the potential use of passive immunization should be considered based on existing successful therapies against many diseases. Here we demonstrate that hyperimmune globulin preparations raised in horses against the recombinant trimeric spike (S) glycoprotein of SARS-CoV-2 in the prefusion conformation provide very high ELISA titers as well as highly potent neutralizing activity against SARS-CoV-2. Five horses were subcutaneously inoculated for 6 weeks with the recombinant S protein (ectodomain, residues 1-1208). Four out of the 5 horses presented a strong immune response. Considering the average of all 5 horses, ELISA titers above 1:1,000,000 and neutralizing titers (PRNT90) reaching 1:14,604 were observed. When compared with the plasma of three convalescent COVID-19 patients, sera of immunized horses displayed approximately 140-fold higher neutralizing titers measured as PRNT90. To prevent eventual side effects caused by horse antiserum, IgG was digested with pepsin and purified by fractional salt precipitation to eliminate Fc fragments, a process that is industrially used for the production of passive immunization F(ab')2 concentrates against rabies, tetanus and snake venoms. The high neutralizing titers against SARS-CoV-2 obtained for the unprocessed sera were confirmed for the F(ab')2 fragments and were 150-fold higher than the PRNT90 neutralizing titers of plasma of three COVID-19 convalescent patients. The great advantage of using the recombinant trimeric S glycoprotein is that it is safe and provides quick adaptive immunity in horses. Our data show the perspective of using hyperimmune anti-SARS-CoV-2 F(ab')2 preparations as a passive immunization therapy in humans, similar to therapies that have been safely used for decades against rabies, tetanus and snake venoms.","Cunha, L. E. R.; Stolet, A. A.; Strauch, M. A.; Pereira, V. A. R.; Dumard, C. H.; Souza, P. N. C.; Fonseca, J. G.; Pontes, F. E.; Meirelles, L. G. R.; Albuquerque, J. W. M.; Sacramento, C. Q.; Fintelman-Rodrigues, N.; Lima, T. M.; Alvim, R. G. F.; Zingali, R.; Oliveira, G. A. P.; Souza, T. M. L.; TANURI, A.; Gomes, A. M. O.; Oliveira, A. C.; Guedes, H. L. M.; Castilho, L. R.; Silva, J. L.","https://www.biorxiv.org/content/10.1101/2020.08.17.254375v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.254375v1?rss=1,2020-08-18,2020-08-18,,False
13,Healthcare workers high COVID-19 infection rate: the source of infections and potential for respirators and surgical masks to reduce occupational infections,"Objective: To analyse the work-related exposure to SARS-CoV-2 and trace the source of COVID-19 infections in tertiary hospitals healthcare workers in light of the used PPE and their ability to maintain social distances and follow governmental restrictions. Design: Cross-sectional study Setting: Tertiary hospitals in Uusimaa region, Finland Participants: Of 1072 enrolled, 866 HCWs (588 nurses, 170 doctors and 108 laboratory and medical imaging nurses) from the Helsinki University Hospital completed the questionnaire by July 15th, 2020. The average age of participants was 42.4 years and 772 (89.0%) were women. The participants answered a detailed questionnaire of their PPE usage, ability to follow safety restrictions, exposure to COVID-19, the source of potential COVID-19 infection and both mental and physical symptoms during the first wave of COVID-19 in Finland. Main outcome measures: All participants with COVID-19 symptoms were tested with either RT-PCR or antibody tests. The infections were traced and categorised based on the location and source of infection. The possibility to maintain social distance and PPE usage during exposure were analyzed. Results: Of the HCWs that participated, 41 (4.7%) tested positive for SARS-CoV-2, marking a substantially higher infection rate than that of the general population (0.3%); 22 (53.6%) of infections were confirmed or likely occupational, including 7 (31.8%) from colleagues. Additionally, 5 (26.3%) of other infections were from colleagues outside the working facilities. 14 (63.6%) of occupational infections occurred while using a surgical mask. No occupational infections were found while using an FFP2/3 respirator and aerosol precautions while treating suspected or confirmed COVID-19 patients. Conclusions: While treating suspected or confirmed COVID-19 patients, HCWs should wear an FFP2/3 respirator and recommended PPE. Maintaining safety distances in the workplace and controlling infections between HCWs should be priorities to ensure safe working conditions.","Oksanen, L.-M. A. H.; Sanmark, E.; Oksanen, S.; Anttila, V.-J.; Paterno, J. J.; Lappalainen, M.; Lehtonen, L.; Geneid, A.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176842v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176842v1?rss=1,2020-08-18,2020-08-18,,True
14,Erythroid precursors and progenitors suppress adaptive immunity and get invaded by SARS-CoV-2,"SARS-CoV-2 infection is associated with lower blood oxygen levels even in patients without hypoxia requiring hospitalization. This discordance illustrates the need for a more unifying explanation as to whether SARS-CoV-2 directly or indirectly affects erythropoiesis. Here we show significantly enriched CD71+ erythroid precursors/progenitors in the blood circulation of COVID-19 patients that have distinctive immunosuppressive properties. A subpopulation of abundant erythroid cells, CD45+CD71+cells, co-express ACE2, TMPRSS2, CD147, CD26 and these can be infected with SARS-CoV-2. In turn, pre-treatment of erythroid cells with dexamethasone significantly diminished ACE2/TMPRSS2 expression and subsequently reduced their infectivity with SARS-CoV-2. Taken together, pathological abundance of erythroid cells might reflect stress erythropoiesis due to the invasion of erythroid progenitors by SARS-CoV-2. This may provide a novel insight into the impact of SARS-CoV-2 on erythropoiesis and hypoxia seen in COVID-19 patients.","Shahbaz, S.; Xu, L.; Osman, M.; Sligl, W.; Shields, J.; Joyce, M.; Tyrrell, L.; Oyegbami, O.; Elahi, S.","https://www.biorxiv.org/content/10.1101/2020.08.18.255927v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255927v1?rss=1,2020-08-18,2020-08-18,,False
15,"Evidence and magnitude of seasonality in SARS-CoV-2 transmission: Penny wise, pandemic foolish?","Abstract: Importance: Intensity and duration of the COVID-19 pandemic, and planning required to balance concerns of saving lives and avoiding economic collapse, could depend significantly on whether SARS-CoV-2 transmission is sensitive to seasonal changes. Objective: Hypothesis is that increasing temperature results in reduced SARS CoV-2 transmission and may help slow the increase of cases over time. Setting: Fifty representative Northern Hemisphere countries meeting specific criteria had sufficient COVID-19 case and meteorological data for analysis. Methods: Regression was used to find relationship between the log of number of COVID-19 cases and temperature over time in 50 representative countries. To summarize the day-day variability, and reduce dimensionality, we selected a robust measure, Coefficient of Time (CT), for each location. The resulting regression coefficients were then used in a multivariable regression against meteorological, country-level and demographic covariates. Results: Median minimum daily temperature showed the strongest correlation with the reciprocal of CT (which can be considered as a rate associated with doubling time) for confirmed cases (adjusted R2=0.610, p= 1.45E-06). A similar correlation was found using median daily dewpoint, which was highly colinear with temperature, and therefore was not used in the analysis. The correlation between minimum median temperature and the rate of increase of the log of confirmed cases was 47% and 45% greater than for cases of death and recovered cases of COVID-19, respectively. This suggests the primary influence of temperature on SARS-CoV2 transmission more than COVID-19 morbidity. Based on the correlation between temperature and the rate of increase in COVID-19, it can be estimated that, between the range of 30 to 100 degrees Fahrenheit, a one degree increase leads to a 1% decrease--and a one degree decrease leads to a 3.7% increase--in the rate of increase of the log of daily confirmed cases. Conclusion: The results suggest that boreal summer months are associated with slower rates of COVID-19 transmission, with the reverse true in winter months. Knowledge of COVID-19 seasonality could prove useful in local planning for phased reductions social interventions and help to prepare for the timing of possible pandemic resurgence during cooler months.","Kaplin, A. I.; Junker, C.; Kumar, A.; de Amorim Ribeiro, M. A.; Yu, E.; Wang, M.; Smith, T.; Rai, S. N.; Bhatnager, A.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176610v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176610v1?rss=1,2020-08-18,2020-08-18,,True
16,Risk factors associated with morbidity and mortality outcomes of COVID-19 patients on the 14th and 28th day of the disease course: a retrospective cohort study in Bangladesh,"Diverse risk factors intercede the outcomes of COVID-19. We conducted this retrospective cohort study to identify the risk factors associated with morbidity and mortality outcomes with a cohort of 1016 COVID-19 patients diagnosed in May 2020. Data were collected by telephone-interview and reviewing records using a questionnaire and checklist. Morbidity (64.4% Vs. 6.0%) and mortality (2.3% Vs. 2.5%) outcomes varied between the 14th and 28th day. Morbidity risk factors included chronic obstructive pulmonary disease (COPD) (RR=1.19, RR=2.68) both on the 14th and 18th day while elderly (AOR=2.56) and smokeless tobacco (SLT) (AOR=2.17) on the 28th day. Mortality risk factors included elderly (AOR=10.14), COPD (RR=5.93), and SLT (AOR=2.25) on the 14th day, and elderly (AOR=24.37) and COPD (RR=2.72) on the 28th day. The morbidity risk was higher with chronic kidney disease (CKD) (RR=3.33) and chronic liver disease (CLD) (RR=3.99) on the 28th day. The mortality risk was higher with coronary heart disease (RR=4.54) and CLD (RR=9.66) on the 14th while with diabetes mellitus (RR=3.08, RR=2.08), hypertension (RR=3.14, RR=2.30), CKD (RR=8.97, RR=2.71), and malignant diseases (RR=10.29) on both 14th and 28th day. We must espouse program interventions considering the morbidity and mortality risk factors to condense the aggressive outcomes of COVID-19.","Islam, M. Z.; Riaz, B. K.; Islam, A. S.; Khanam, F.; Akhter, J.; Choudhury, R.; Farhana, N.; Uddin, M. J.; Efa, S. S.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176586v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176586v1?rss=1,2020-08-18,2020-08-18,,True
17,Spike protein mutational landscape in India: Could Mullers ratchet be a future game-changer for COVID-19?,"The dire need of effective preventive measures and treatment approaches against SARS CoV 2 virus, causing COVID 19 pandemic, calls for an in-depth understanding of its evolutionary dynamics with attention to specific geographic locations, since lockdown and social distancing to prevent the virus spread could lead to distinct localized dynamics of virus evolution within and between countries owing to different environmental and host specific selection pressures. To decipher any correlation between SARS CoV 2 evolution and its epidemiology in India, we studied the mutational diversity of spike glycoprotein, the key player for the attachment, fusion and entry of virus to the host cell. For this, we analyzed the sequences of 630 Indian isolates as available in GISAID database till June 07, 2020, and detected the spike protein variants to emerge from two major ancestors, Wuhan-Hu-1/2019 and its D614G variant. Average stability of the docked spike protein host receptor (SR) complexes for these variants correlated strongly (R2=0.96) with the fatality rates across Indian states. However, while more than half of the variants were found unique to India, 67% of all variants showed lower stability of SR complex than the respective ancestral variants, indicating a possible fitness loss in recently emerged variants, despite a continuous increase in mutation rate. These results conform to the sharply declining fatality rate countrywide (>7 fold during April 11 and June 28, 2020). Altogether, while we propose the potential of SR complex stability to track disease severity, we urge an immediate need to explore if SARS CoV 2 is approaching mutational meltdown in India.","Banerjee, R.; Basak, K.; Ghosh, A.; Rajachandran, V.; Sureka, K.; Ganguly, D.; Chattopadhyay, S.","https://www.biorxiv.org/content/10.1101/2020.08.18.255570v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255570v1?rss=1,2020-08-18,2020-08-18,,False
18,Data-Driven Development of a Small-Area COVID-19 Vulnerability Index for the United States,"As the COVID-19 pandemic continues to surge in the United States, it has become clear that infection risk is higher in certain populations, particularly socially and economically marginalized groups. Social risk factors, together with other demographic and community characteristics, may reveal local variations and inequities in COVID risk that could be useful for targeting testing and interventions. Yet to date, rates of infection and estimations of COVID risk are typically reported at the county and state level. In this study we develop a small area vulnerability index based on publicly-available sociodemographic data and 668,428 COVID diagnoses reported in 4,803 ZIP codes in the United States (15% of all ZIP codes). The outcome was COVID-19 diagnosis rates per 100,000 people by ZIP code. Explanatory variables included sociodemographic characteristics obtained from the 2018 American Community Survey 5-year estimates. Bayesian multivariable techniques were used to capture complexities of spatial data and spatial autocorrelation and identify individual risk factors and derive their respective weights in the index. COVID-19 diagnosis rates varied from zero to 29,508 per 100,000 people. The final vulnerability index showed that higher population density, higher percentage of noninsured, nonwhite race and Hispanic ethnicity were positively associated with COVID-19 diagnosis rates. Our findings indicate disproportionate risk of COVID-19 infection among some populations and validate and expand understanding of these inequities, integrating several risk factors into a summary index reflecting composite vulnerability to infection. This index can provide local public health and other agencies with evidence-based metrics of COVID risk at a geographical scale that has not been previously available to most US communities.","amram, o.; Amiri, S.; Thorn, E. L.; Mansfield, J. J.; Mellacheruvu, P.; Monsivais, P.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176248v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176248v1?rss=1,2020-08-18,2020-08-18,,True
19,SARS-CoV-2 Infection and Transmission Depends on Heparan Sulfates and Is Blocked by Low Molecular Weight Heparins,"The current pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and new outbreaks worldwide highlight the need for preventive treatments. Although angiotensin converting enzyme 2 (ACE2) is the primary receptor for SARS-CoV-2, we identified heparan sulfate proteoglycans expressed by epithelial cells, alveolar macrophages and dendritic cells as co-receptors for SARS-CoV-2. Low molecular weight heparins (LMWH) blocked SARS-CoV-2 infection of epithelial cells and alveolar macrophages, and virus dissemination by dendritic cells. Notably, potent neutralizing antibodies from COVID-19 patients interfered with SARS-CoV-2 binding to heparan sulfate proteoglycans, underscoring the importance of heparan sulfate proteoglycans as receptors and uncover that SARS-CoV-2 binding to heparan sulfates is an important mechanism for neutralization. These results have imperative implications for our understanding of SARS-CoV-2 host cell entry and reveal an important target for novel prophylactic intervention.","Bermejo-Jambrina, M.; Eder, J.; Kaptein, T. M.; Helgers, L. C.; Brouwer, P. J.; van Hamme, J. L.; Vlaar, A. P.; van Baarle, F. E. H. P.; de Bree, G. J.; Nijmeijer, B. M.; Kootstra, N. A.; van Gils, M. J.; Sanders, R. W.; Geijtenbeek, T. B. H.","https://www.biorxiv.org/content/10.1101/2020.08.18.255810v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255810v1?rss=1,2020-08-18,2020-08-18,,False
20,Seeding of outbreaks of COVID-19 by contaminated fresh and frozen food,"An explanation is required for the re-emergence of COVID-19 outbreaks in regions with apparent local eradication. Recent outbreaks have emerged in Vietnam, New Zealand and parts of China where there had been no cases for some months. Importation of contaminated food and food packaging is a feasible source for such outbreaks and a source of clusters within existing outbreaks. Such events can be prevented if the risk is better appreciated.","Fisher, D.; Reilly, A.; Kang Eng Zheng, A.; Cook, A. R.; Anderson, D.","https://www.biorxiv.org/content/10.1101/2020.08.17.255166v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.255166v1?rss=1,2020-08-18,2020-08-18,,False
21,Generalized linear models provide a measure of virulence for specific mutations in SARS-CoV-2 strains,"This study aims to highlight SARS-COV-2 mutations which are associated with increased or decreased viral virulence. We utilize, genetic data from all strains available from GISAID and countries' regional information such as deaths and cases per million as well as covid-19-related public health austerity measure response times. Initial indications of selective advantage of specific mutations can be obtained from calculating their frequencies across viral strains. By applying modelling approaches, we provide additional information that is not evident from standard statistics or mutation frequencies alone. We therefore, propose a more precise way of selecting informative mutations. We highlight two interesting mutations found in genes N (P13L) and ORF3a (Q57H). The former appears to be significantly associated with decreased deaths and cases per million according to our models, while the latter shows an opposing association with decreased deaths and increased cases per million. Moreover, protein structure prediction tools show that the mutations infer conformational changes to the protein that significantly alter its structure when compared to the reference protein.","Oulas, A.; Zanti, M.; Tomazou, M.; Zachariou, M.; Minadakis, G.; Bourdakou, M. M.; Pavlidis, P.; Spyrou, G. M.","https://www.biorxiv.org/content/10.1101/2020.08.17.253484v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.253484v1?rss=1,2020-08-18,2020-08-18,,False
22,The effect of whey protein on viral infection and replication of SARS-CoV-2 and pangolin coronavirus in vitro,"Since the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human breastmilk, little is known about the antiviral property of human breastmilk to SARS-CoV-2 and its related pangolin coronavirus (GX_P2V). Here we present for the first time that whey protein from human breastmilk effectively inhibited both SARS-CoV-2 and GX_P2V by blocking viral attachment, entry and even post-entry viral replication. Moreover, human whey protein inhibited infectious virus production proved by the plaque assay. We found that whey protein from different species such as cow and goat also showed anti-coronavirus properties. And commercial bovine milk also showed similar activity. Interestingly, the main antimicrobial components of breastmilk, such as Lactoferrin and IgA antibody, showed limited anti-coronavirus activity, indicating that other factors of breastmilk may play the important anti-coronavirus role. Taken together, we reported that whey protein inhibits SARS-CoV-2 and its related virus of GX_P2V. These results rule out whey protein as a direct-acting inhibitor of SARS-CoV-2 and GX_P2V infection and replication and further investigation of its molecular mechanism of action in the context of COVID-19.","Fan, H.; Luo, Y.; Hong, B.; Wang, L.; Jin, X.; Chen, Y.; Hu, Y.; Li, T.; Zhuang, H.; Zhou, Y.-H.; Tong, Y.-G.; Xiang, K.","https://www.biorxiv.org/content/10.1101/2020.08.17.254979v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.254979v1?rss=1,2020-08-18,2020-08-18,,False
23,In-depth blood proteome profiling analysis revealed distinct functional characteristics of plasma proteins between severe and non-severe COVID-19 patients,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected over ten million patients worldwide. Although most coronavirus disease 2019 (COVID-19) patients have a good prognosis, some develop severe illness. Markers that define disease severity or predict clinical outcome need to be urgently developed as the mortality rate in critical cases is approximately 61.5%. In the present study, we performed in-depth proteome profiling of undepleted plasma from eight COVID-19 patients. Quantitative proteomic analysis using the BoxCar method revealed that 91 out of 1,222 quantified proteins were differentially expressed depending on the severity of COVID-19. Importantly, we found 76 proteins, previously not reported, which could be novel prognostic biomarker candidates. Our plasma proteome signatures captured the host response to SARS-CoV-2 infection, thereby highlighting the role of neutrophil activation, complement activation, platelet function, and T cell suppression as well as proinflammatory factors upstream and downstream of interleukin-6, interleukin-1B, and tumor necrosis factor. Consequently, this study supports the development of blood biomarkers and potential therapeutic targets to aid clinical decision-making and subsequently improve prognosis of COVID-19.","Park, J.; Kim, H.; Kim, S. Y.; Kim, Y.; Lee, J.-S.; Seong, M.-W.; Han, D.","https://www.biorxiv.org/content/10.1101/2020.08.18.255315v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255315v1?rss=1,2020-08-18,2020-08-18,,False
24,IFITM proteins promote SARS-CoV-2 infection in human lung cells,"Interferon-induced transmembrane proteins (IFITMs 1, 2 and 3) restrict numerous viral pathogens and are thought to prevent infection by severe acute respiratory syndrome coronaviruses (SARS-CoVs). However, most evidence comes from single-round pseudoparticle infection of cells artificially overexpressing IFITMs. Here, we confirmed that overexpression of IFITMs blocks pseudoparticle infections mediated by the Spike proteins of {beta}-coronaviruses including pandemic SARS-CoV-2. In striking contrast, however, endogenous IFITM expression promoted genuine SARS-CoV-2 infection in human lung cells both in the presence and absence of interferon. IFITM2 was most critical for efficient entry of SARS-CoV-2 and enhanced virus production from Calu-3 cells by several orders of magnitude. IFITMs are expressed and further induced by interferons in the lung representing the primary site of SARS-CoV-2 infection as well as in other relevant tissues. Our finding that IFITMs enhance SARS-CoV-2 infection under conditions approximating the in vivo situation shows that they may promote viral invasion during COVID-19.","Prelli Bozzo, C.; Nchioua, R.; Volcic, M.; Wettstein, L.; Weil, T.; Krueger, J.; Heller, S.; Conzelmann, C.; Mueller, J. A.; Gross, R.; Zech, F.; Schuetz, D.; Koepke, L.; Stuerzel, C. M.; Schueler, C.; Stenzel, S.; Braun, E.; Weiss, J.; Sauter, D.; Muench, J.; Stenger, S.; Sato, K.; Kleger, A.; Goffinet, C.; Sparrer, K. M. J.; Kirchhoff, F.","https://www.biorxiv.org/content/10.1101/2020.08.18.255935v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.18.255935v1?rss=1,2020-08-18,2020-08-18,,False
25,A Lymph Node Targeted Amphiphile Vaccine Induces Potent Cellular and Humoral Immunity to SARS-CoV-2,"The SARS-CoV-2 pandemic has led to public health, economic, and social consequences that mandate urgent development of effective vaccines to contain or eradicate infection. To that end, we evaluated a novel amphiphile (AMP) vaccine adjuvant, AMP-CpG, composed of diacyl lipid-modified CpG, admixed with the SARS-CoV-2 Spike-2 receptor binding domain protein as a candidate vaccine (ELI-005) in mice. AMP immunogens are efficiently delivered to lymph nodes, where innate and adaptive immune responses are generated. Compared to alum, AMP immunization induced >25-fold higher antigen-specific T cells which produced multiple Th1 cytokines and trafficked into lung parenchyma and respiratory secretions. Antibody responses favored Th1 isotypes (IgG2bc, IgG3) and potently neutralized Spike-2-ACE2 receptor binding, with titers 265-fold higher than the natural immune response from convalescent COVID-19 patients; responses were maintained despite 10-fold dose-reduction in Spike antigen. Both cellular and humoral immune responses were preserved in aged mice. These advantages merit clinical translation to SARS-CoV-2 and other protein subunit vaccines.","Steinbuck, M. P.; Seenappa, L. M.; Jakubowski, A.; McNeil, L. K.; Haqq, C. M.; DeMuth, P. C.","https://www.biorxiv.org/content/10.1101/2020.08.17.251728v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.17.251728v1?rss=1,2020-08-18,2020-08-18,,False
26,End-to-End Protocol for the Detection of SARS-CoV-2 from Built Environments,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019, is a respiratory virus primarily transmitted from person to person through inhalation of droplets or aerosols, laden with viral particles. However, as some studies have shown, virions can remain infectious for up to 72 hours on surfaces, which can lead to transmission through contact. For this reason, a comprehensive study was conducted to determine the efficiency of protocols to recover SARS-CoV-2 from surfaces in built environments. This end-to-end (E2E) study showed that the effective combination of monitoring SARS-CoV-2 on surfaces include using an Isohelix swab as a collection tool, DNA/RNA Shield as a preservative, an automated system for RNA extraction, and reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) as the detection assay. Using this E2E approach, this study showed that, in some cases, SARS-CoV-2 viral standards were still recovered from surfaces as detected by RT-qPCR for as long as eight days even after bleach treatment. Additionally, debris associated with specific built environment surfaces appeared to negatively impact the recovery of RNA, with Amerstat inhibition as high as 90% when challenged with an inactivated viral control. Overall, it was determined that this E2E protocol required a minimum of 1,000 viral particles per 25 cm2 to successfully detect virus from test surfaces. When this method was employed to evaluate 368 samples collected from various built environmental surfaces, all samples tested negative, indicating that the surfaces were either void of virus or below the detection limit of the assay.","Parker, C. W.; Singh, N.; Tighe, S.; Blachowicz, A.; Wood, J. M.; Seuylemezian, A.; Vaishampayan, P.; Urbaniak, C.; Hendrickson, R.; Laaguiby, P.; Clark, K.; Clement, B. G.; O'Hara, N. B.; Couto-Rodriguez, M.; Bezdan, D.; Mason, C.; Venkateswaran, K.","https://www.medrxiv.org/content/10.1101/2020.08.16.20172668v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20172668v1?rss=1,2020-08-18,2020-08-18,,True
27,Abnormal Upregulation of Cardiovascular Disease Biomarker PLA2G7 Induced by Proinflammatory Macrophages in COVID-19 patients,"BACKGROUND. Coronavirus disease 2019 (COVID-19) triggers distinct patterns of pneumonia progression with multiorgan disease, calling for cell- and/or tissue-type specific host injury markers. METHODS. An integrated hypothesis-free single biomarker analysis framework was performed on nasal swabs (n=484) from patients with COVID-19 in GSE152075. The origin of candidate biomarker was assessed in single-cell RNA data (GSE145926). The candidate biomarker was validated in a cross-sectional cohort (n=564) at both nucletide and protein levels. RESULTS. Phospholipase A2 group VII (PLA2G7) was identified as a candidate biomarker in COVID-19. PLA2G7 was predominantly expressed by proinflammatory macrophages in lungs emerging with progression of COVID-19. In the validation stage, PLA2G7 was found in patients with COVID-19 and pneumonia, especially in severe pneumonia, rather than patients suffered mild H1N1 influenza infection. The positive rates of PLA2G7 ranging from 29.37% to 100.00% were positively correlated with not only viral loads in patients with COVID-19 but also severity of pneumonia in non COVID-19 patients. Although Ct values of PLA2G7 in severe pneumonia was siginificantly lower than that in moderate pneumonia (P=7.2e-11), no differences were observed in moderate pneumonia with COVID-19 between severe pneumonia without COVID-19 (P=0.81). Serum protein levels of PLA2G7, also known as lipoprotein-associated phospholipase A2 (Lp-PLA2), were further found to be elevated and beyond the upper limit of normal in patients with COVID-19, especially among the re-positive patients. CONCLUSIONS. We firstly identified and validated PLA2G7, a biomarker for cardiovascular diseases (CVDs), was abnormally enhanced in COVID-19 patients at both nucletide and protein aspects. These findings provided indications into the prevalence of cardiovascular involvements seen in COVID-19 patients. PLA2G7 could be a hallmark of COVID-19 for monitoring disease progress and therapeutic response.","LI, Y.; JIANG, Y.; ZHANG, Y.; LI, N.; YIN, Q.; LIU, L.; LV, X.; LIU, Y.; LI, A.; FANG, B.; LI, J.; YE, H.; YANG, G.; CUI, X.; LIU, Y.; QU, Y.; LI, C.; LI, J.; LI, D.; WANG, S.; GAI, Z.; ZHAN, F.; LIANG, M.","https://www.medrxiv.org/content/10.1101/2020.08.16.20175505v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20175505v1?rss=1,2020-08-18,2020-08-18,,True
28,Interobserver Agreement of Lung Ultrasound Findings of COVID-19,"Background: Lung ultrasound (LUS) may be used in the diagnostic evaluation of patients with COVID-19. An abnormal LUS is associated with increased risk for ICU admission in COVID-19. Previously described LUS manifestations for COVID-19 include B-lines, consolidations, and pleural thickening. The interrater reliability (IRR) of these findings for COVID-19 is unknown. Research Question: What is the interrater reliability of lung ultrasound findings in patients with RT-PCR confirmed COVID-19? Study Design and Methods: This study was conducted at conducted at two academic medical centers between 03/2020-06/2020. Nine physicians (hospitalists: n=4; emergency medicine: n=5) independently evaluated n=20 LUS scans (n=180 independent observations) collected from RT-PCR confirmed COVID-19 patients. These studies were randomly selected from an image database consisting of COVID-19 patients evaluated in the emergency department with portable ultrasound devices. Physicians were blinded to any patient information or previous LUS interpretation. Kappa values were used to calculate IRR. Results: There was substantial IRR on the following items: normal LUS scan (K=0.79 [95% CI: 0.72-0.87]), presence of B-lines (K=0.79 [95% CI: 0.72-0.87]), >=3 B-lines observed (K=0.72 [95% CI: 0.64-0.79]). Moderate IRR was observed for the presence of any consolidation (K=0.57 [95% CI: 0.50-0.64]), subpleural consolidation (K=0.49 [95% CI: 0.42-0.56]), and presence of effusion (K=0.49 [95% CI: 0.41-0.56]). Fair IRR was observed for pleural thickening (K=0.23 [95% CI: 0.15-0.30]). Interpretation: Many LUS manifestations for COVID-19 appear to have moderate to substantial IRR across providers from multiple specialties utilizing differing portable devices. The most reliable LUS findings with COVID-19 may include the presence/count of B-lines or determining if a scan is normal. Clinical protocols for LUS with COVID-19 may require additional observers for the confirmation of less reliable findings such as consolidations.","Kumar, A.; Weng, Y.; Graglia, S.; Chung, S.; Duanmu, Y.; Lalani, F.; Gandhi, K.; Lobo, V.; Jensen, T.; Kugler, J.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176156v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176156v1?rss=1,2020-08-18,2020-08-18,,True
29,Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs,"Mass testing is fundamental to face the pandemic caused by the coronavirus SARS-CoV-2 discovered at the end of 2019. To this aim, it is necessary to establish reliable, fast and cheap tools to detect viral particles in biological material so to identify the people capable to spread the infection. We demonstrate that a colorimetric biosensor based on gold nanoparticle (AuNP) interaction induced by SARS-CoV-2 lends itself as an outstanding tool for detecting viral particles in nasal and throat swabs. The extinction spectrum of a colloidal solution of multiple viral-target gold nanoparticles - AuNPs functionalized with antibodies targeting three surface proteins of SARS-CoV-2 (spike, envelope and membrane) - is redshifted in few minutes when mixed to a solution containing the viral particle. The optical density of the mixed solution measured at 560 nm was compared to the threshold cycle (Ct) of a Real Time-PCR (gold standard for detecting the presence of viruses) finding that the colorimetric method is able to detect very low viral load with a detection limit approaching that of RT-PCR. Since the method is sensitive to the infecting viral particle rather than to its RNA, the achievements reported here open new perspective not only in the context of the current and possible future pandemics, but also in microbiology as the biosensor proves itself to be a powerful though simple tool for measuring the viral particle concentration.","Della Ventura, B.; Cennamo, M.; Minopoli, A.; Campanile, R.; Bolletti Censi, S.; Terracciano, D.; Portella, G.; Velotta, R.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175489v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175489v1?rss=1,2020-08-18,2020-08-18,,True
30,Longitudinal SARS-CoV-2 serosurveillance of over ten thousand health care workers in the Providence Oregon cohort.,"ABSTRACT Frontline healthcare workers (HCW) are a high-risk population for SARS-CoV-2 infection. Here we present results from a large serosurveillance study of 10,019 asymptomatic HCW conducted during April-May 2020, in eight hospital medical centers across the state of Oregon, USA during the initial peak of the pandemic. Free and voluntary testing was performed at 14 +/- 3 day intervals, over a 4-week window at each site, utilizing a lab-developed ELISA based on the Epitope Diagnostics COVID-19 nucleocapsid IgG detection Kit. We identified 253 SARS-CoV-2 IgG seropositive individuals among 10,019 total participants, representing a cross-sectional seroprevalence of 2.53%. Subgroup analysis identified differential seropositivity by job role, ranging from 8.03% among housekeepers, odds ratio 3.17 (95% CI 1.59-5.71), to 0.00% among anesthesiologists, odds ratio 0.00 (95% CI 0-0.26), both of which were significant. Over the course of the study, 17 seroconversions (0.25%) and 101 seroreversions (1.50%) were identified. Self-reported SARS-CoV-2 swab qPCR testing, when compared with subsequent serology on study, showed only modest agreement, {kappa} = 0.47 (95% CI 0.32-0.62). Overall, these findings demonstrate relatively low seroprevalence and very low seroconversion rates among HCW in Oregon, USA, over a period in which aggressive social distancing measures were in place. The high rate of seroreversion observed in this cohort, and the relatively high discordance between SARS-CoV-2 serology and swab qPCR, highlight limitations of current detection methods, and stress the need for development of novel assessment methodologies to more accurately identify exposure (and/or immunity) to SARS-CoV-2 in this population.","Leidner, R.; Frary, A.; Cramer, J.; Ball, D.; Weerasinghe, R.; Schmidt, M.; Jin, J.; Luzzi, V.; Saitman, A.; Young, J. A.; Leidner, D.; Sawa, K.; Marsal, S.; Olson, K.; Frisco, N.; Compton-Phillips, A.; Urba, W.; Piening, B.; Bifulco, C.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176107v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176107v1?rss=1,2020-08-18,2020-08-18,,True
31,COVID-19 ICU and mechanical ventilation patient characteristics and outcomes - A systematic review and meta-analysis,"Background Insight into COVID-19 intensive care unit (ICU) patient characteristics, rates and risks of invasive mechanical ventilation (IMV) and associated outcomes as well as any regional discrepancies is critical in this pandemic for individual case management and overall resource planning. Methods and Findings Electronic searches were performed for reports through May 1 2020 and reports on COVID-19 ICU admissions and outcomes were included using predefined search terms. Relevant data was subsequently extracted and pooled using fixed or random effects meta-analysis depending on heterogeneity. Study quality was assessed by the NIH tool and heterogeneity was assessed by I2 and Q tests. Baseline patient characteristics, ICU and IMV outcomes were pooled and meta-analyzed. Pooled odds ratios (pOR) were calculated for clinical features against ICU, IMV mortality. Subgroup analysis was carried out based on patient regions. A total of twenty-eight studies comprising 12,437 COVID-19 ICU admissions from seven countries were meta-analyzed. Pooled ICU admission rate was 21% [95% CI 0.12-0.34] and 69% of cases needed IMV [95% CI 0.61-0.75]. ICU and IMV mortality were 28.3% [95% CI 0.25-0.32], 43% [95% CI 0.29-0.58] and ICU, IMV duration was 7.78 [95% CI 6.99-8.63] and 10.12 [95% CI 7.08-13.16] days respectively. Besides confirming the significance of comorbidities and clinical findings of COVID-19 previously reported, we found the major correlates with ICU mortality were IMV [pOR 16.46, 95% CI 4.37-61.96], acute kidney injury (AKI) [pOR 12.47, 95% CI 1.52-102.7], and acute respiratory distress syndrome (ARDS) [pOR 6.52, 95% CI 2.66-16.01]. Subgroup analyses confirm significant regional discrepancies in outcomes. Conclusions This is the most comprehensive systematic review and meta-analysis of COVID-19 ICU and IMV cases and associated outcomes to date and the only analysis to implicate IMV's associtaion with COVID-19 ICU mortality. The significant association of AKI, ARDS and IMV with mortality has implications for ICU resource planning for AKI and ARDS as well as research into optimal ventilation strategies for patients. Regional differences in outcome implies a need to develop region specific protocols for ventilatory support as well as overall treatment.","Chang, R.; Elhusseiny, K. M.; Yeh, Y.-C.; Sun, W.-z.","https://www.medrxiv.org/content/10.1101/2020.08.16.20035691v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20035691v1?rss=1,2020-08-18,2020-08-18,,True
32,Impacts on Surgery Resident Education at a first wave COVID-19 epicenter,"Background: This study aims to identify the effects of the COVID-19 pandemic on surgical resident training and education at Danbury Hospital. Methods: We conducted an observational study at a Western Connecticut hospital heavily affected by the first wave of the COVID-19 pandemic to assess its effects on surgical residents, focusing on surgical education, clinical experience, and operative skills development. Objective data was available through recorded work hours, case logs, and formal didactics. In addition, we created an anonymous survey to assess resident perception of their residency experience during the pandemic. Results: There are 22 surgical residents at our institution; all were included in the study. Resident weekly duty hours decreased by 23.9 hours with the majority of clinical time redirected to caring for COVID-19 patients. Independent studying increased by 1.6 hours (26.2%) while weekly didactics decreased by 2.1 hours (35.6%). The operative volume per resident decreased by 65.7% from 35.0 to 12.0 cases for the period of interest, with a disproportionately high effect on junior residents, who experienced a 76.2% decrease. Unsurprisingly, 70% of residents reported a negative effect of the pandemic on their surgical skills. Conclusions: During the first wave of the COVID-19 pandemic, surgical residents' usual workflows changed dramatically, as much of their time was dedicated to the critical care of patients with COVID-19. However, the consequent opportunity cost was to surgery-specific training; there was a significant decrease in operative cases and time spent in surgical didactics, along with elevated concern about overall preparedness for their intended career.","Ostapenko, A.; McPeck, S.; Liechty, S.; Kleiner, D.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176073v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176073v1?rss=1,2020-08-18,2020-08-18,,True
33,Heart disease mortality during the early pandemic period in the United States.,"Importance: The coronavirus disease 2019 (COVID-19) outbreak has been associated with decreases in acute myocardial infarction diagnoses (AMI) and admissions in the United States. Whether this affected heart disease deaths is unknown. Objective: To determine whether changes in heart disease deaths occurred during the early pandemic period in the US, we analyzed areas without large COVID-19 outbreaks. This isolated the effect of decreased healthcare-seeking behavior during the early outbreak. Design, Setting, and Participants: We performed an observational study of heart disease-specific mortality using National Center for Health Statistics data (NCHS). Weekly provisional counts were disaggregated by jurisdiction of occurrence during 2019 and 2020 for all-cause deaths, COVID-19 deaths, and heart disease deaths. For the primary analysis, jurisdictions were included if; 1) There was no all-cause excess mortality during the early pandemic period (weeks 14-17, 2020); 2) The completeness of that data was estimated by NCHS to be >97% as of July 22, 2020, and; 3) Decreases in emergency department (ED) visits occurred during the study period. We compared heart disease death rates during the early pandemic period with corresponding weeks in 2019 and a pre-pandemic control period of 2020 as a sensitivity analysis. Incident rate and rate ratios were calculated. Exposure: The US COVID-19 outbreak. Main Outcomes and Measures: Incidence of heart disease deaths. Results: Twelve states met the primary inclusion criteria, capturing 747,375,188 person-weeks for the early pandemic period and 740,987,984 person-weeks for the 2019 control period. The mean incidence rate (per 100,000 person-weeks) for heart disease in states without excess deaths during the early pandemic period was 3.95 (95% CI 3.83 to 4.06) versus 4.19 (95% CI 4.14 to 4.23) during the corresponding period in 2019. The incident rate ratio (2020/2019) was 0.91 (95% CI 0.87 to 0.97). No state recorded an increase from either the corresponding period in 2019 or the 2020 pre-pandemic control period. Two states recorded fewer heart disease deaths. Conclusions and Relevance: This observational study found a decrease in heart disease deaths during the early US outbreak in regions without significant COVID-19 burdens, despite decreases in ED utilization. Long term follow-up data are needed.","Faust, J. S.; Lin, Z.; Wright, K. N.; Di Iorio, M. A.; Walsh, C. D.; Krumholz, H.","https://www.medrxiv.org/content/10.1101/2020.08.16.20175406v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20175406v1?rss=1,2020-08-18,2020-08-18,,True
34,Acute Peritoneal Dialysis During the COVID-19 Pandemic at Bellevue Hospital in New York City,"The COVID-19 pandemic created an unprecedented strain on hospitals in New York City. Although practitioners focused on the pulmonary devastation, resources for the provision of dialysis proved to be more constrained. To deal with these shortfalls, NYC Health and Hospitals/Bellevue, NYU Brooklyn, NYU Medical Center and the New York Harbor VA Healthcare System, put together a plan to offset the anticipated increased needs for kidney replacement therapy. Prior to the pandemic, peritoneal dialysis was not used for acute kidney injury at Bellevue Hospital. We were able to rapidly establish an acute peritoneal dialysis program at Bellevue Hospital for acute kidney injury patients in the intensive care unit. A dedicated surgery team was assembled to work with the nephrologists for bedside placement of the peritoneal dialysis catheters. A multi-disciplinary team was trained by the lead nephrologist to deliver peritoneal dialysis in the intensive care unit. Between April 8, 2020 and May 8, 2020, 39 peritoneal dialysis catheters were placed at Bellevue Hospital. 38 patients were successfully started on peritoneal dialysis. As of June 10, 2020, 16 patients recovered renal function. One end stage kidney disease patient was converted to peritoneal dialysis and was discharged. One catheter was poorly functioning, and the patient was changed to hemodialysis before recovering renal function. There were no episodes of peritonitis and nine incidents of minor leaking, which resolved. Some patients received successful peritoneal dialysis while being ventilated in the prone position. In summary, despite severe shortages of staff, supplies and dialysis machines during the COVID-19 pandemic, we were able to rapidly implement a de novo peritoneal dialysis program which enabled provision of adequate kidney replacement therapy to all admitted patients who needed it. Our experience is a model for the use of acute peritoneal dialysis in crisis situations.","Caplin, N. J.; Zhdanova, O.; Tandon, M.; Thompson, N.; Patel, D.; Somroo, Q.; Ranjeeta, F.; Joseph, L.; Scherer, J.; Joshi, S.; Dyal, B.; Chawla, H.; Lakshmi, S.; Bails, D.; Benstein, J.; Goldfarb, D. S.; Gelb, B.; Amerling, R.; Charytan, D. M.","https://www.medrxiv.org/content/10.1101/2020.08.16.20175992v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20175992v1?rss=1,2020-08-18,2020-08-18,,True
35,On the use of growth models for forecasting epidemic outbreaks with application to COVID-19 data,"The initial phase dynamics of an epidemic without containment measures is commonly well modeled using exponential growth models. However, in the presence of containment measures, the exponential model becomes less appropriate. Under the implementation of an isolation measure for detected infectives, we propose to model epidemic dynamics by fitting a flexible growth model curve to reported positive cases and to infer the overall epidemic dynamics by introducing information on the detection/testing effort and recovery and death rates. The resulting modeling approach is close to the SIQR (Susceptible- Infectious-Quarantined-Recovered) model framework. We focused on predicting the peaks (time and size) in positive cases, actives cases and new infections. We applied the approach to data from the COVID-19 outbreak in Italy. Fits on limited data before the observed peaks illustrate the ability of the flexible growth model to approach the estimates from the whole data.","TOVISSODE, C. F.; LOKONON, B. E.; GLELE KAKAI, R.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176057v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176057v1?rss=1,2020-08-18,2020-08-18,,True
36,Protection Level and Reusability of a Modified Full-Face Snorkel Mask as Alternative Personal Protective Equipment for Healthcare Workers During the COVID-19 Pandemic,"The worldwide outbreak of the COVID-19 drastically increased pressure on medical resources and highlighted the need for rapidly available, large-scale and low-cost personal protective equipment (PPE). In this work, an alternative full-face mask is adapted from a modified snorkel mask to be used as PPE with two medical grade filters and a 3D-printed adapter. As the mask covers the eyes, mouth and nose, it acts as a full-face shield, providing additional protection to healthcare workers. The filtration efficiency of different medical filters is measured for particles below 300 nm to cover the size of the SARS-CoV-2 and small virus-laden droplets. The filtration performance of the adapted full-face mask is characterized using NaCl particles below 500 nm and different fitting scenarios. The mask is compared to a commercial respirator and characterized according to the EN 149 standard, demonstrating that the protection fulfills the requirements for the FFP2 level (filtering face-piece 2, stopping at least 94% of airborne particles). The device shows a good resistance to several cycles of decontamination (autoclaving and ethanol immersion), is easy to be produced locally at low cost and helps addressing the shortage in FFP2 masks and face shields by providing adequate protection to healthcare workers against particles below 500 nm.","Schmitt, J.; Jones, L. S.; Aeby, E. A.; Gloor, C.; Moser, B.; Wang, J.","https://www.medrxiv.org/content/10.1101/2020.08.16.20176081v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20176081v1?rss=1,2020-08-18,2020-08-18,,True
37,Study of Coronavirus Impact on Parisian Population from April to June using Twitter and Text Mining Approach,"The fast spreading of coronavirus name covid19, generated the actual pandemic forcing to change daily activities. Health Councils of each country promote health policies, close borders and start a partial or total lockdown. One of the first countries in Europe with high impact was Italy. Besides at the end of April, one country with a shared border was on the top of 10 countries with more total cases, then France started with its own battle to beat coronavirus. This paper studies the impact of coronavirus in the poopulation of Paris, France from April 23 to June 18, using Text Mining approach, processing data collected from Social Network and using trends related of searching. First finding is a decreasing pattern of publications/interest, and second is related to health crisis and economical impact generated by coronavirus.","Chire Saire, J. E.; Oblitas Cruz, J. F.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175810v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175810v1?rss=1,2020-08-18,2020-08-18,,True
38,Multisystem inflammatory syndrome in children related to COVID-19: A systematic review,"Importance. In April 2020, multiple reports of an association between a hyperinflammatory, Kawasaki-like condition and SARS-CoV-2 were published and termed as pediatric inflammatory multisystem syndrome (PIMS) or multisystem inflammatory syndrome (MIS). A thorough characterization of this syndrome (demographics, presentation, diagnosis, and outcome) is currently lacking. Objective. We aimed to perform a systematic review of published cases of this novel multisystem inflammatory syndrome in children associated with COVID-19. Evidence review. A literature search of Pubmed, Embase, BioRxiv, MedRxiv and COVID-19 specific research repositories (Cochrane COVID-19 Study Register and the World Health Organization (WHO) COVID-19 Global Research Database) was conducted from December 30th, 2019 to June 30th, 2020. Publications describing inflammatory syndromes associated with COVID-19 were included. Of 333 unique publications, 229 records were excluded based on title and abstract. After screening the full text, 40 observational studies and case reports were included, comprising 687 cases (published between May 9th, 2020 and June 30th, 2020). Findings. In contrast to classic Kawasaki disease, epidemiological enrichment for adolescents (median age 9 [6.0-12.3]) and ethnic minorities (35.8% black and 24.5% Hispanic/Latino) was observed. There was a male predominance (59.1%). Apart from obesity (24.4%), pre-existing conditions were infrequent. The majority suffered from gastrointestinal (87.2%) and cardiocirculatory (79.2%) manifestations. Respiratory symptoms (51.2%) were less frequent. Over half of patients (56.3%) presented with hemodynamic shock, and critical care interventions were often necessary (inotropics (56.5%), mechanical ventilation (22.9%), non-invasive ventilation (30.6%), extracorporal membrane oxygenation (ECMO;4.5%)). Anti-SARS-CoV-2 IgG and RT-PCR were positive in respectively 69.4% and 36.7%. Eleven deaths were reported (1.6%). The RCPCH case definition proved to be most comprehensive comprising all single cases. In contrast, WHO and CDC MIS definitions are more stringent, with the CDC case definition often missing severe cases requiring intensive care (n = 33 out of 95 cases). Conclusions and Relevance. This novel pediatric multisystem hyperinflammatory condition, associated with COVID-19, is characterized by a severe and heterogeneous disease spectrum. Despite frequent intensive care interventions, mortality rate was low and short-term outcome favorable. Long-term follow-up of possible chronic complications and additional clinical research, to elucidate the underlying immunological pathogenesis and possible genetic predisposition is crucial.","Hoste, L.; Van Paemel, R.; Haerynck, F.","https://www.medrxiv.org/content/10.1101/2020.08.17.20173641v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20173641v1?rss=1,2020-08-18,2020-08-18,,True
39,Investigation into Quality of Life and Psychological Status of Different Populations during COVID-19 : A study concerning Surrounding Areas of Wuhan,"Objective To investigate different populations' quality of life and psychological status in surrounding areas of Wuhan during COVID-19 pandemic. Methods The data of 248 residents living in Anhui from February 4 to 6 of 2020 were collected through network survey including age, gender, occupation, the World Health Organization Quality of Life measurement Scale short form (World Health Organization Quality of Life instrument - brief, WHOQOL BREF), Zung Self rating Anxiety Scale (Self- rating Anxiety Scale, SAS and Zung Self-Rating Depression Scale (SDS). Those surveyed, divided into two groups: medical staff (129 cases) and non-medical staff (119 cases), were made statistic analysis according to the factors mentioned above. Results The WHOQOL-BREF of medical staff in this region was lower than that of non-medical staff in the fields of physiology, psychology, social relations and environment, among whom female medical staff scored significantly lower than that of male medical staff in four fields. There was no significant statistical difference in SAS and SDS scores between the two groups, and gender had no significant influence on SAS and SDS scores of medical staff. Conclusion During the COVID-19 pandemic, medical staff enjoyed a lower quality of life of in surrounding areas of Wuhan than that of non-medical staff, and female medical staff even lower, which should arouse social concern.","Liu, Z.; Mu, J.; Fan, W.","https://www.medrxiv.org/content/10.1101/2020.08.15.20158725v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20158725v1?rss=1,2020-08-18,2020-08-18,,True
40,Quantifying the efficiency of non-pharmaceutical interventions against SARS-COV-2 transmission in Europe,"Since the emergence of SARS-CoV-2, governments around the World have implemented a combination of public health responses based on non-pharmaceutical interventions (NPIs), with significant social and economic consequences. Though most European countries have overcome the first epidemic wave, it remains of high priority to quantify the efficiency of different NPIs to inform preparedness for an impending second wave. In this study, combining capture-recapture methods with Bayesian inference in an age-structured mathematical model, we use a unique European dataset compiled by the European Centre for Disease Control (ECDC) to quantify the efficiency of 24 NPIs and their combinations (referred to as public health responses, PHR) in reducing SARS-Cov-2 transmission rates in 32 European countries. Of 166 unique PHR tested, we found that median decrease in viral transmission was 74%, which is enough to suppress the epidemic. PHR efficiency was positively associated with the number of NPIs implemented. We found that bans on mass gatherings had the largest effect among NPIs, followed by school closures, teleworking, and stay home orders. Partial implementation of most NPIs resulted in lower than average response efficiency. This first large-scale estimation of NPI and PHR efficiency against SARS-COV-2 transmission in Europe suggests that a combination of NPIs targeting different population groups should be favored to control future epidemic waves.","Garchitorena, A.; Gruson, H.; Cazelles, B.; ROCHE, B.","https://www.medrxiv.org/content/10.1101/2020.08.17.20174821v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20174821v1?rss=1,2020-08-18,2020-08-18,,True
41,SARS-CoV-2 antibody responses in children with MIS-C and mild and severe COVID-19,"SARS-CoV-2 antibody responses in children remain poorly characterized. Here, we show that pediatric patients with multisystem inflammatory syndrome in children (MIS-C) possess higher SARS-CoV-2 spike IgG titers compared to those with severe coronavirus disease 2019 (COVID-19), likely reflecting a longer time since onset of infection in MIS-C patients.","Anderson, E. M.; Diorio, C.; Goodwin, E. C.; McNerney, K. O.; Weirick, M. E.; Gouma, S.; Bolton, M. J.; Arevalo, C. P.; Chase, J.; Hicks, P.; Manzoni, T. B.; Baxter, A. E.; Andrea, K. P.; Burudpakdee, C.; Lee, J. H.; Vella, L. A.; Henrickson, S. E.; Harris, R. M.; Wherry, E. J.; Bates, P.; Bassiri, H.; Behrens, E. M.; Teachey, D. T.; Hensley, S.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176552v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176552v1?rss=1,2020-08-18,2020-08-18,,True
42,Evolving Virulence? Decreasing COVID-19 Complications among Massachusetts Healthcare Workers: A Cohort Study,"The hypothesis of attenuating SARS-CoV-2 virulence has been raised. We examined the temporal distribution of COVID-19 complications (ER visits, hospitalization, intubation/code, and/or death) among healthcare workers in one system that applied uniform screening criteria throughout the research period, and found the complication rate significantly decreased after April 15, 2020.","Lan, F.-Y.; Filler, R.; Mathew, S.; Iliaki, E.; Osgood, R.; Bruno-Murtha, L. A.; Kales, S. N.","https://www.medrxiv.org/content/10.1101/2020.08.17.20176636v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.17.20176636v1?rss=1,2020-08-18,2020-08-18,,True
43,ESTIMATING PREVALENCE AND TIME COURSE OF SARS-CoV-2 BASED ON NEW HOSPITAL ADMISSIONS AND PCR TESTS,"Data posted in the COVID 19 tracking website for RT-PCR (PCR) results and hospital admissions are used to estimate the prevalence of the SARS-CoV-2 pandemic in the United States (1). Hospital admissions mitigate positive sampling bias in PCR tests due to their initially limited test numbers and application as a diagnostic, instead of a surveying tool. As of July 31, the United States' cumulative recovered population is estimated at 47% or 155 million. The remaining susceptible population is 53%, or 47% excepting the 6% infectious population. The estimated mortality rate of the cumulative recovered population is 0.09% death per case. New York and Massachusetts show SARS-CoV-2 prevalence of 87% and 55%, respectively. Likewise, each state exhibits relatively low current positive PCR results at 1 % and 1.7%. Also, these states show about twice the mortality rate of the nation. Florida, California, and Texas showed recovered population percent around 40%, higher current PCR positive test results ranging from 7% to 13%. A higher recovered population mitigates the current positive value attainable by limiting the infectivity rate Re. This approach provides an alternate source of information on the pandemic's full time course since the serological testing only views a narrow time slice of its history due to the transient nature of the antibody response and its graduated expression dependency on the severity of the disease. The deficiency of serological testing to estimate the recovered population is made even more acute due to the large proportion of asymptomatic and sub-clinical cases in the COVID-19 pandemic","Gonzalez, J. E.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175653v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175653v1?rss=1,2020-08-17,2020-08-17,,True
44,"SARS-Cov-2-, HIV-1-, Ebola-neutralizing and anti-PD1 clones are predisposed","Antibody repertoire refers to the totality of the superbly diversified antibodies within an individual to cope with the vast array of possible pathogens. Despite this extreme diversity, antibodies of the same clonotype, namely public clones, have been discovered among individuals. Although some public clones could be explained by antibody convergence, public clones in naive repertoire or virus-neutralizing clones from not infected people were also discovered. All these findings indicated that public clones might not occur by random and they might exert essential functions. However, the frequencies and functions of public clones in a population have never been studied. Here, we integrated 2,449 Rep-seq datasets from 767 donors and discovered 5.07 million public clones - ~10% of the repertoire are public in population. We found 38 therapeutic clones out of 3,390 annotated public clones including anti-PD1 clones in healthy people. Moreover, we also revealed clones neutralizing SARS-CoV-2, Ebola, and HIV-1 viruses in healthy individuals. Our result demonstrated that these clones are predisposed in the human antibody repertoire and may exert critical functions during particular immunological stimuli and consequently benefit the donors. We also implemented RAPID - a Rep-seq Analysis Platform with Integrated Databases, which may serve as a useful tool for others in the field.","Zhang, Y.; Xu, Q.; Zeng, H.; Wang, M.; Zhang, Y.; Lan, C.; Yang, X.; Zhu, Y.; Chen, Y.; Wang, Q.; Tang, H.; Zhang, Y.; Wu, J.; Wang, C.; Xie, W.; Ma, C.; Guan, J.; Guo, S.; Chen, S.; Chang, C.; Yang, W.; Wei, L.; Ren, J.; Yu, X.; Zhang, Z.","https://www.biorxiv.org/content/10.1101/2020.08.13.249086v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.249086v1?rss=1,2020-08-17,2020-08-17,,False
45,A lesson from COVID-19 on inaccessibility of web-based information for disabled populations worldwide,"Many government websites and mobile content are inaccessible for people with vision, hearing, and cognitive disabilities. The COVID-19 pandemic highlighted these disparities when health authority website information, critical in providing resources for curbing the spread of the virus, remained inaccessible for disabled populations. The Web Content Accessibility Guidelines provide comparatively universally accepted guidelines for website accessibility. We utilized these parameters to examine the number of countries with or without accessible health authority websites. The resulting data indicate a dearth of countries with websites accessible for persons with disabilities. Methods of information dissemination must take into consideration individuals with disabilities, particularly in times of global health crises.","Dror, A. A.; Layous, E.; Mizrachi, M.; Daoud, A.; Eisenbach, N.; Morozov, N. G.; Srouji, S.; Avraham, K. B.; Sela, E.","https://www.biorxiv.org/content/10.1101/2020.08.16.252676v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.16.252676v1?rss=1,2020-08-17,2020-08-17,,False
46,"SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways","Severe acute respiratory syndrome corona-virus 2 (SARS-CoV-2), the etiologic agent of the coronavirus disease 2019 (COVID-19), has a catastrophic effect on human health and society. Clinical findings indicated that the suppression of innate antiviral immunity, especially the type I and III interferon (IFN) production, contributes to the pathogenesis of COVID-19. However, how SARS-CoV-2 evades antiviral immunity still needs further investigations. Here, we reported that the open reading frame 9b (ORF9b) protein encoded by the SARS-CoV-2 genome inhibits the activation of type I and III IFN response by targeting multiple molecules of innate antiviral signaling pathways. SARS-CoV-2 ORF9b impaired the induction of type I and III IFNs by Sendai virus or the dsRNA mimic poly (I:C). SARS-CoV-2 ORF9b inhibits the activation of type I and III IFNs induced by the components of cytosolic dsRNA-sensing pathways of RIG-I/MDA5-MAVS signaling, including RIG-I, MDA-5, MAVS, TBK1, and IKK{varepsilon} rather than IRF3-5D, the active form of IRF3. SARS-CoV-2 ORF9b also suppressed the induction of type I and III IFNs by TRIF and STING, the adaptor protein of endosome RNA-sensing pathway of TLR3-TRIF signaling and the adaptor protein of cytosolic DNA-sensing pathway of cGAS-STING signaling, respectively. Mechanistically, SARS-CoV-2 ORF9b protein interacts with RIG-I, MDA-5, MAVS, TRIF, STING, TBK1, and prevents TBK1 phosphorylation, thus impeding the phosphorylation and nuclear trans-localization of IRF3 activation. Overexpression of SARS-CoV-2 ORF9b facilitates the replication of the vesicular stomatitis virus. Therefore, SARS-CoV-2 ORF9b negatively regulates antiviral immunity, thus, facilitate virus replication. This study contributes to our understanding of the molecular mechanism of how SARS-CoV-2 impaired antiviral immunity and providing an essential clue to the pathogenesis of COVID-19.","Han, L.; Zhuang, M.-W.; Zheng, Y.; Zhang, J.; Nan, M.-L.; Wang, P.-H.; Gao, C.","https://www.biorxiv.org/content/10.1101/2020.08.16.252973v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.16.252973v1?rss=1,2020-08-17,2020-08-17,,False
47,A pilot study to see any Change of the Nasal and Oropharyngeal Microbiota with Prolonged Use of Medical Masks during the COVID-19 Outbreak,"Background: The outbreak of coronavirus disease 2019 (COVID-19) has played havoc on the healthcare system and society. Many international guidelines have put forward various measures to control the spread and, using various quality masks seems to be the most important amongst them. This was a cross-sectional pilot study to see any alterations in the bacterial flora of the nasal and the oropharyngeal (OP) microbiota with the use of medical masks over prolonged periods during this COVID-19 outbreak. Methods: Nasal and oropharyngeal swabs were collected using proper international guidelines from 30 healthy healthcare workers matching pre-set inclusion criteria, who gave written informed consent. The swabs were used for gram stain as well as culture and sensitivity analysis using standard methods. Results: In general, we found that the oropharyngeal microflora harboured a more diverse population of bacteria (n=13) than the nasal microflora (n=5). The predominant bacterial flora was found to Staphylococcus epidermidis in the nasal cavity and Streptococcus viridans in the oropharyngeal cavity. There was no growth in 8 (26.68%) samples of oropharynx and 3 (10%) of nasal samples, with one patient having no growth in both the samples. The commonest resistant antibiotic from both the cavity cultures was benzylpenicillin (nasal flora 80% and OP flora 47.37%). Conclusion: This small pilot study has shown a reassuring aspect of no change in the typical bacterial microflora species of the nasal and OP cavity with prolonged use of medical masks. This is the first study to show this convincing evidence during the COVID-19 outbreak and also in healthy healthcare workers who have to wear masks over long durations.","Roy, S.; Majumder, P.; Bhattacharjee, K.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175067v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175067v1?rss=1,2020-08-17,2020-08-17,,True
48,Pulmonary cavitation; an under-recognized late complication of severe COVID-19 lung disease,"Background: Radiological findings of the novel coronavirus disease 2019 (COVID-19) pulmonary disease have been well documented and range from scattered ground-glass infiltrates in milder cases to confluent ground-glass change, dense consolidation, and crazy paving in the critically ill, however, lung cavitation has not been described in these patients. Objectives: To assess the incidence of pulmonary cavitation and describe its characteristics and evolution. Methods: A retrospective review of all patients admitted to our institution with COVID-19 was undertaken and imaging reviewed to identify patients who developed pulmonary cavitation. Results: Twelve out of 689 (1.7%) patients admitted to our institution with COVID-19 developed pulmonary cavitation, comprising 3.3% (n=12/359) of those with COVID-19 pneumonia, and 11% (n=12/110) of those admitted to the intensive care unit. We describe the imaging characteristics of the cavitation and present the clinical, pharmacological, laboratory, and microbiological parameters for these patients. In this cohort six patients have died while another remains critically ill and unlikely to survive. Conclusion: Cavitary lung disease in patients with severe COVID-19 disease is not uncommon, and is associated with a high level of morbidity and mortality.","Zoumot, Z.; Bonilla, M.-F.; Wahla, A. S.; Shafiq, I.; Uzbeck, M.; El-Lababidi, R. M.; Hamed, F.; Abuzakouk, M.; El-Kaissi, M.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175869v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175869v1?rss=1,2020-08-17,2020-08-17,,True
49,Efficient Deep Network Architecture for COVID-19 Detection Using Computed Tomography Images,"Globally the devastating consequence of COVID-19 or Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV-2) has posed danger on the life of living beings. Doctors and scientists throughout the world are working day and night to combat the proliferation or transmission of this deadly disease in terms of technology, finances, data repositories, protective equipment, and many other services. Rapid and efficient detection of COVID-19 reduces the rate of spreading this deadly disease and early treatment improve the recovery rate. In this paper, we proposed a new framework to exploit powerful features extracted from the autoencoder and Gray Level Co-occurence Matrix (GLCM), combined with random forest algorithm for the efficient and fast detection of COVID-19 using computed tomographic images. The model's performance is evident from its 97.78% accuracy, 96.78% recall, and 98.77% specificity.","Goel, C.; Kumar, A.; Dubey, S. K.; Srivastava, V.","https://www.medrxiv.org/content/10.1101/2020.08.14.20170290v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.14.20170290v1?rss=1,2020-08-17,2020-08-17,,True
50,"Impact of COVID-19 on Primary Care Mental Health Services: A Descriptive, Cross-Sectional Timeseries of Electronic Healthcare Records","Introduction. There are growing concerns about the impact of the COVID-19 pandemic on mental health. With government-imposed restrictions as well as a general burden on healthcare systems, the pandemic has the potential to disrupt the access to, and delivery of, mental healthcare. Ultimately, this could potentially lead to unmet needs of individuals requiring mental health support. Methods. Electronic healthcare records from primary care psychological therapy services (Improving Access to Psychological Therapy) in England were used to examine changes in access to mental health services and service delivery during early stages of the COVID-19 pandemic. A cross-sectional, descriptive timeseries was conducted using data from 1st January 2019 to 24th May 2020 across five NHS trusts to examine patterns in referrals to services (n = 171,823) and appointments taking place (n = 865,902). Results. The number of patients accessing mental health services dropped by an average of 55% in the 9 weeks after lockdown was announced, reaching a maximum reduction of 74% in the initial 3 weeks after lockdown in the UK. As referrals began to increase again, there was a relatively faster increase in referrals from Black, Asian, and ethnic minority groups as well an increase in referrals from more densely populated areas. Despite a reduction in access, service providers adapted to infection control guidance by rapidly shifting to remote delivery of care. Interpretation. Services were able to rapidly adapt to provide continuity of care in mental healthcare. However, patients accessing services reduced dramatically, potentially placing a future burden on service providers to treat a likely backlog of patients in addition to a possible excess of patients as the long-term consequences of the pandemic become more apparent. Despite the observational nature of the data, which should be noted, the present study can inform the planning of service provision and policy.","Bauer-Staeb, C. M. M.; Davis, A.; Smith, T. R.; Betts, D.; Wilsher, W.; Eldridge, C.; Griffith, E.; Faraway, J. J.; Button, K. S.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175562v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175562v1?rss=1,2020-08-17,2020-08-17,,True
51,The effect of smoking on COVID-19 symptom severity: Systematic review and meta-analysis,"Background: Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SAR2-COV-2), and was first identified in Wuhan, China in December of 2019, but quickly spread to the rest of the world, causing a pandemic. While some studies have found no link between smoking status and severe COVID-19, others demonstrated a significant one. The present study aimed to determine the relationship between smoking and clinical COVID-19 severity via a systematic meta-analysis approach. Methods: We searched the Google Scholar, PubMed, Scopus, Web of Science, and Embase databases to identify clinical studies suitable for inclusion in this meta-analysis. Studies reporting smoking status and comparing non-severe and severe patients were included. Non-severe cases were described as mild, common type, non-intensive care unit (ICU) treatment, survivors, and severe cases as critical, need for ICU, refractory, and non-survivors. Results: A total of 16 articles detailing 11322 COVID-19 patients were included. Our meta-analysis revealed a relationship between a history of smoking and severe COVID-19 cases (OR=2.17; 95% CI: 1.37-3.46; P <.001). Additionally, we found an association between the current smoking status and severe COVID-19 (OR=1.51; 95% CI: 1.12-2.05; P <.008). In 10.7% (978/9067) of non-smokers, COVID-19 was severe, while in active smokers, severe COVID-19 occurred in 21.2% (65/305) of cases. Conclusion: Active smoking and a history of smoking are clearly associated with severe COVID-19. The SARS-COV-2 epidemic should serve as an impetus for patients and those at risk to maintain good health practices and discontinue smoking.","Gulsen, A.; Arpinar Yigitbas, B.; Uslu, B.; Droemann, D.; Kilinc, O.","https://www.medrxiv.org/content/10.1101/2020.08.15.20102699v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20102699v1?rss=1,2020-08-17,2020-08-17,,True
52,Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Outpatients in Saudi Arabia,"Background: Healthcare systems globally has been challenged following the COVID-19 pandemic, since late 2019. Multiple approaches and strategies have been performed to relieve the pressure and support existing healthcare systems. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were established across Saudi Arabia. Methods: A cross-sectional study included 2,733 eligible patients subjected to MOH treatment protocol (hydroxychloroquine and zinc) and revisited the clinics within 3-7 days after treatment initiation. This study aimed to assess the safety outcome and reported adverse events from hydroxychloroquine use among suspected COVID-19 patients. The data was collected through an electronic link and cross-checked with that of the national database (Health Electronic Surveillance Network, HESN) and reports from the MOH Morbidity and Mortality (M&M) Committee. Results: Majority of the cases were males (70.4%). Upon reassessing the studied participants within 3-7 days, 240 patients (8.8%) discontinued the treatment protocol because of the development of side effects (4.1%) and for non-clinical reasons in the remaining (4.7%). Medication side effects overall were reported among (6.7%) of all studied participants, including mainly cardiovascular adverse events (2.5%), followed by gastrointestinal (GI) symptoms (2.4%). No Intensive Care Unit (ICU) admission or death were reported among these patients. Conclusion: In our study, results show that the use of hydroxychloroquine for COVID-19 patients in mild to moderate cases in an outpatient setting, within the protocol recommendation and inclusion/exclusion criteria, is safe, highly tolerable, and with minimum side effects.","Mohana, A.; Suliman, T.; Mahmoud, N.; Hassanein, M.; Alfaifi, A.; Alenazi, E.; Radwan, N.; Alkhalifah, N.; Elkady, E.; Almohaizeie, A.; AboGazalah, F.; AbdulKareem, K.; AlGhofaili, F.; Jokhdar, H.; Alrabiah, F.","https://www.medrxiv.org/content/10.1101/2020.08.16.20175752v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20175752v1?rss=1,2020-08-17,2020-08-17,,True
53,The influence of climate factors on COVID-19 transmission in Malaysia: An autoregressive integrated moving average (ARIMA) model,"Background A unique concern pertaining to the spread of COVID-19 across countries is the asymmetry of risk and the irrational fear of a new pandemic and its possible serious consequences. This study aimed to perform a time series analysis on the association between climate factors and daily cases of COVID-19 in Malaysia up to 15 July 2020. The second objective was to predict daily new cases using a forecasting technique. To address within-country variations, the analysis was extended to the state level with Sarawak state as an example. Methodology/Principal Findings Datasets on the daily confirmed cases and climate variables in Malaysia and Sarawak state were obtained from publicly accessible official websites. A descriptive analysis was performed to characterize all the important variables over the study period. An autoregressive integrated moving average (ARIMA) model was introduced using daily cases as the dependent variable and climate parameters as the explanatory variables. For Malaysia, the findings suggest that, ceteris paribus, the number of COVID-19 cases decreased with increasing average temperature (p=0.003) or wind speed (p=0.029). However, none of the climate parameters showed a significant relationship with the number of COVID-19 cases in Sarawak state. Forecasts from the ARIMA models showed that new daily COVID-19 cases had already reached the outbreak level and a decreasing trend in both settings. Holding other parameters constant, a small number of new cases (approximately a single digit) is a probable second wave in Sarawak state, Conclusions/Significance The findings suggest that climate parameters and forecasts are helpful for reducing the uncertainty in the severity of future COVID-19 transmission. A highlight is that forecasts will be a useful tool for making decisions and taking the appropriate interventions to contain the spread of the virus in the community.","Naing, C.; Ni, H.; Aung, H. H.; Wan Ling, E. C.; Mak, J. W.","https://www.medrxiv.org/content/10.1101/2020.08.14.20175372v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.14.20175372v1?rss=1,2020-08-17,2020-08-17,,True
54,A data-driven epidemiological model to explain the Covid-19 pandemic in multiple countries and help in choosing mitigation strategies,"Accurate models are fundamental to understand the dynamics of the COVID-19 pandemic and to evaluate different mitigation strategies. Here, we present a multi-compartmental model that fits the epidemiological data for eleven countries, despite the reduced number of fitting parameters. This model consistently explains the data for the daily infected, recovered, and dead over the first six months of the pandemic. The good quality of the fits makes it possible to explore different scenarios and evaluate the impact of both individual and collective behaviors and government- level decisions to mitigate the epidemic. We identify robust alternatives to lockdown, such as self- protection measures, and massive testing. Furthermore, communication and risk perception are fundamental to modulate the success of different strategies. The fitting/simulation tool is publicly available for use and test of other models, allowing for comparisons between different underlying assumptions, mitigation measures, and policy recommendations.","Beira, M. J.; Kumar, A.; Perfeito, L.; Goncalves-Sa, J.; Sebastiao, P. J.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175588v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175588v1?rss=1,2020-08-17,2020-08-17,,True
55,SARS-Coronavirus-2 nucleocapsid protein measured in blood using a Simoa ultra-sensitive immunoassay differentiates COVID-19 infection with high clinical sensitivity.,"The COVID-19 pandemic continues to have an unprecedented impact on societies and economies worldwide. Despite rapid advances in diagnostic test development and scale-up, there remains an ongoing need for SARS-CoV-2 tests which are highly sensitive, specific, minimally invasive, cost-effective and scalable for broad testing and surveillance. Here we report development of a highly sensitive single molecule array (Simoa) immunoassay on the automated HD-X platform for the detection of SARS-CoV-2 Nucleocapsid protein (N-protein) in venous and capillary blood (fingerstick). In pre-pandemic and clinical sample sets, the assay has 100% specificity and 97.4% sensitivity for serum / plasma samples. The limit of detection (LoD) estimated by titration of inactivated SARS-CoV-2 virus is 0.2 pg/ml, corresponding to 0.05 Median Tissue Culture Infectious Dose (TCID50) per ml, > 2000 times more sensitive than current EUA approved antigen tests. No cross-reactivity to other common respiratory viruses, including hCoV229E, hCoVOC43, hCoVNL63, Influenza A or Influenza B, was observed. We detected elevated N-protein concentrations in symptomatic, asymptomatic, and pre-symptomatic PCR+ individuals using capillary blood from a finger-stick collection device. The Simoa SARS-CoV-2 N-protein assay has the potential to detect COVID-19 infection via antigen in blood with similar or better performance characteristics of molecular tests, while also enabling at home and point of care sample collection.","Shan, D.; Johnson, J. M.; Fernandes, S. C.; Mendes, M.; Suib, H.; Holdridge, M.; Burke, E. M.; Beauregard, K. G.; Zhang, Y.; Cleary, M.; Xu, S.; Yao, X.; Patel, P. P.; Plavina, T.; Wilson, D. H.; Chang, L.; Kaiser, K. M.; Natterman, J.; Schmidt, S. V.; Latz, E.; Hrusovsky, K.; Mattoon, D.; Ball, A. J.","https://www.medrxiv.org/content/10.1101/2020.08.14.20175356v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.14.20175356v1?rss=1,2020-08-17,2020-08-17,,True
56,GIS-based spatial modeling to identify factors affecting COVID-19 incidence rates in Bangladesh,"The outbreak of the COVID-19 pandemic is an unprecedented shock throughout the world which leads to generate a massive social, human, and economic crisis. However, there is a lack of research on geographic modeling of COVID-19 as well as identification of contributory factors affecting the COVID-19 in the context of developing countries. To fulfill the gap, this study aimed to identify the potential factors affecting the COVID-19 incidence rates at the district-level in Bangladesh using spatial regression model (SRM). Therefore, data related to 32 demographic, economic, weather, built environment, health, and facilities related factors were collected and analyzed to explain the spatial variability of this disease incidence. Three global (Ordinary least squares (OLS), spatial lag model (SLM) and spatial error model (SEM)) and one local (geographically weighted regression (GWR)) SRMs were developed in this study. The results of the models showed that four factors significantly affected the COVID-19 incidence rates in Bangladesh. Those four factors are urban population percentage, monthly consumption, number of health workers, and distance from the capital. Among the four developed models, the GWR model performed the best in explaining the variation of COVID-19 incidence rates across Bangladesh with a R square value of 78.6%. Findings from this research offer a better insight into the COVID-19 situation and would help to develop policies aimed to prevent the future epidemic crisis.","Rahman, M. H.; Zafri, N. M.; Ashik, F. R.; Waliullah, M.","https://www.medrxiv.org/content/10.1101/2020.08.16.20175976v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.16.20175976v1?rss=1,2020-08-17,2020-08-17,,True
57,COVID-19 among nursing staff: Settings and regional differences,"Purpose This study was carried out to describe settings of and regional differences in the occurrence of COVID-19 among nursing staff, analysing COVID-19 symptoms, testing and diagnosis procedures. Design We used an online survey to conduct this cross-sectional study among nursing staff in different settings. Data collection was carried out between 12 May and 13 July 2020. Methods The survey included questions that allowed us to collect demographic data (e.g. age), professional qualifications (e.g. nurse, nurse aid) and data regarding the federal states and settings in which the participants worked. In additon, we asked the participants to describe their COVID-19 symptoms, if any were experienced, and the result of COVID-19 testing that they underwent. We used descriptive statistics as well as bivariate analysis methods to calculate differences. Findings More than 80% of the nursing staff (N = 2600) were women, nearly half of these staff members worked in the province of Styria and about three-quarters worked in hospitals. In general, nearly every sixth nurse reported experiencing COVID-19 symptoms. We found statistically significant differences between the settings and the federal provinces with regard to the COVID-19 symptoms reported, but not the test results. The highest porportion of nurses who experienced symptoms worked in lower Austria and in the primary care sector. In total, 1.6% of the participating nurses were tested for COVID-19, as well as about 1% of the nurses who worked in the nursing homes. The highest number of tests were carried out in Vienna followed by the province of Burgenland. In total, all of the nurses who underwent testing were diagnosed with COVID-19. Conclusions Only 1% of the nurses who worked in nursing homes were tested. This group of nurses takes care of the most vulnerable and high-risk group in Austrian society. Therefore, the nursing home staff should have the possibility to be tested even though they did not experience/report any symptoms. The highest prorportion of nurses who experienced symptoms worked in the primary care sector. In the future during a pandemic, health care staff should be comprehensively tested in all settings. Clinical Relevance Providing insights into COVID-19 symptoms experienced by nursing staff workforce and testing for COVID-19 can help us address these aspects in future pandemics more efficiently. In addition, these insights can help to shift the perspectives from critical and acute settings to other settings, e.g. nursing homes. This is an important change in perspectives, as these nurses have worked with the most vulnerable and high-risk group during the COVID-19 pandemic. Ensuring the safety of nursing home residents and providing, high-quality nursing care and interventions can reduce hospital admission rates, decrease health care costs during such pandemics and might even reduce secondary morbidity and mortality.","Hoedl, M.; Eglseer, D.; Bauer, S.","https://www.medrxiv.org/content/10.1101/2020.08.14.20174797v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.14.20174797v1?rss=1,2020-08-17,2020-08-17,,True
58,Universal PCR and antibody testing demonstrate little to no transmission of SARS-CoV-2 in a rural community,"Background: The absence of systematic surveillance for SARS-CoV-2 has curtailed accurate appraisal of transmission intensity. Our objective was to perform case detection of an entire rural community to quantify SARS-CoV-2 transmission using PCR and antibody testing. Methods: We conducted a cross-sectional survey of the prevalence and cumulative incidence of SARS-CoV-2 infection in the rural town of Bolinas, California (population 1,620), four weeks following shelter-in-place orders. Residents and county essential workers were tested between April 20th-24th, 2020. Prevalence by PCR and seroprevalence combining data from two forms of antibody testing were performed in parallel (Abbott ARCHITECT IgG to nucleocapsid protein and in-house IgG ELISA to the receptor binding domain). Results: Of 1,891 participants, 1,312 were confirmed Bolinas residents (>80% community ascertainment). Zero participants were PCR positive. Assuming 80% sensitivity, it would have been unlikely to observe these results (p<0.05) if there were >3 active infections in the community. Based on antibody results, estimated prevalence of prior infection was 0.16% (95% CrI: 0.02%, 0.46%). Seroprevalence estimates using only one of the two tests would have been higher, with greater uncertainty. The positive predictive value (PPV) of a positive result on both tests was 99.11% (95% CrI: 95.75%, 99.94%), compared to PPV 44.19%-63.32% (95% CrI range 3.25%-98.64%) if only one test was utilized. Conclusions: Four weeks following shelter-in-place, active and prior SARS-CoV-2 infection in a rural Northern California community was extremely rare. In this low prevalence setting, use of two antibody tests increased the PPV and precision of seroprevalence estimates.","Appa, A.; Takahashi, S.; Rodriguez-Barraquer, I.; Chamie, G.; Sawyer, A.; CLIAHUB Consortium,; Duarte, E.; Hakim, J.; Turcios, K.; Vinden, J.; Janson, O.; Manglik, A.; Peluso, M. J.; Deeks, S. G.; Henrich, T. J.; Torres, L.; Rodgers, M.; Hackett, J.; Chiu, C. Y.; Havlir, D.; Greenhouse, B.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175786v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175786v1?rss=1,2020-08-17,2020-08-17,,True
59,Behavioral preventive measures and the use of medicines and herbal products among the public in response to Covid-19 in Bangladesh: A cross-sectional study,"The present study was conducted to assess the behavioral preventive measures and the use of medicines and herbal foods/products among the public in response to Covid-19. A cross-sectional survey was conducted from 27 June to 20 July 2020, and 1222 people participated. Kruskal-Wallis test was used to identify the differences in behavioral preventive practices across different demographic categories. To identify the factors associated with the use of preventive medicines and herbal foods/products, multivariable logistic regression was performed. Most participants adopted the recommended preventive practices such as washing hands more frequently (87.5%), staying home more often (85.5%), avoiding crowds (86%), and wearing masks (91.6%). About half of the smokers reported a decreased rate of smoking during the pandemic. Also, 14.8% and 57.6% of the participants took medicines and herbal foods/products as preventive measures against Covid-19. Arsenicum album and Zinc supplements were the most commonly used preventive medicines. Gender, age, and fear of Covid-19 were significantly associated with the use of both preventive medicines and herbal products. For the management of Covid-19 related symptoms, Paracetamols, Fexofenadine, and Zinc supplements were used most often. Most participants sought information from non-medical sources while using medicines and herbal products. Moreover, potentially inappropriate and unnecessary use of drugs were identified.","Ahmed, I.; Hasan, M.; Akter, R.; Sarkar, B. K.; Rahman, M.; Sarker, M. S.; Samad, M. A.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175513v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175513v1?rss=1,2020-08-17,2020-08-17,,True
60,COVID-19 TRANSMISSION DYNAMICS IN INDIA WITH EXTENDED SEIR MODEL,"India is one of the most harshly affected countries due to COVID epidemic. Early implementation of lockdown protocols were useful to control certain parameters of transmission dynamics, but the numbers are consistently increasing in later months. India population is divided into different clusters on the basis of population density and population mobility, even varying resource availability and since the recent cases are coming from throughout the country, it allows us to model an overall average of the country. In this study, we try to prove the efficiency of using the SEIR epidemiological model for different rate study analysis for COVID epidemic in India. Along with it we derived newer components for better forecast of the pandemic in India. We found that there is a decrease in R0 value, but still the epidemic is not under control. The percentage of infected patients being admitted into ICU for critical care is around 9.986%, while the chances of recovery of critical patients being admitted to the ICU seem to be slim at 79.9% of the admitted being dead.","MALI REDDY, B. R.; SINGH, A.; SRIVASTAVA, P.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175703v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175703v1?rss=1,2020-08-17,2020-08-17,,True
61,IL-6 and IL-10 as predictors of disease severity in COVID 19 patients: Results from Meta-analysis and Regression,"Objectives: SARS-CoV-2, an infectious agent behind the ongoing COVID-19 pandemic, induces high levels of cytokines in patients contributing to the disease patho-physiology. Nonetheless, exact association and contribution of particular cytokines towards COVID-19 pathology remains poorly understood. This study performed a comprehensive meta-analysis to establish association between induced cytokines and COVID-19 disease severity to help in prognosis and clinical management. Methods: Scientific literature was searched to identify 18 clinical studies. Standardized mean difference (SMD) for cytokines IL-2, IL-4, IL-6, IL-10, TNF- and IFN-{gamma} between severe and non-severe COVID-19 patient groups were summarized using random effects model. A classifier was built using logistic regression model with cytokines having significant SMD as covariates. Results: Out of the 6 cytokines, IL-6 and IL-10 showed statistically significant SMD across the studies synthesized. Classifier with mean values of both IL-6 and IL-10 as covariates performed well with accuracy of ~ 92% that was significantly higher than accuracy reported in literature with IL-6 and IL-10 as individual covariates. Conclusions: Simple panel proposed by us with only two cytokine markers can be used as predictors for fast diagnosis of patients with higher risk of COVID-19 disease deterioration and thus can be managed well for a favourable prognosis.","Dhar, S. K.; K, V.; Damodar, S.; Gujar, S.; Das, M.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175844v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175844v1?rss=1,2020-08-17,2020-08-17,,True
62,SARS-CoV-2 Antibody Responses Correlate with Resolution of RNAemia But Are Short-Lived in Patients with Mild Illness,"SARS-CoV-2-specific antibodies, particularly those preventing viral spike receptor binding domain (RBD) interaction with host angiotensin-converting enzyme 2 (ACE2) receptor, could offer protective immunity, and may affect clinical outcomes of COVID-19 patients. We analyzed 625 serial plasma samples from 40 hospitalized COVID-19 patients and 170 SARS-CoV-2-infected outpatients and asymptomatic individuals. Severely ill patients developed significantly higher SARS-CoV-2-specific antibody responses than outpatients and asymptomatic individuals. The development of plasma antibodies was correlated with decreases in viral RNAemia, consistent with potential humoral immune clearance of virus. Using a novel competition ELISA, we detected antibodies blocking RBD-ACE2 interactions in 68% of inpatients and 40% of outpatients tested. Cross-reactive antibodies recognizing SARS-CoV RBD were found almost exclusively in hospitalized patients. Outpatient and asymptomatic individuals' serological responses to SARS-CoV-2 decreased within 2 months, suggesting that humoral protection may be short-lived.","Roltgen, K.; Wirz, O. F.; Stevens, B. A.; Powell, A. E.; Hogan, C. A.; Najeeb, J.; Hunter, M.; Sahoo, M. K.; Huang, C.; Yamamoto, F.; Manalac, J.; Otrelo-Cardoso, A. R.; Pham, T. D.; Rustagi, A.; Rogers, A. J.; Shah, N. H.; Blish, C. A.; Cochran, J. R.; Nadeau, K. C.; Jardetzky, T. S.; Zehnder, J. L.; Wang, T. T.; Kim, P. S.; Gombar, S.; Tibshirani, R.; Pinsky, B. A.; Boyd, S. D.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175794v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175794v1?rss=1,2020-08-17,2020-08-17,,True
63,"Rapid, sensitive and high-throughput screening method for detection of SARS-CoV-2 antibodies by bio layer interferometry","Present pandemic scenario, there exists an unmet global need for the development of a rapid and sensitive method for the detection of SARS-CoV-2 infection. The available options for identification of SARS-CoV-2 infection are detection of viral RNA by qRT-PCR, Antigen or Antibody testing by serological methods. Even though many kits available commercially but none of them are rapid, sensitive and high throughput. OnCovid total antibody assay is a diagnostic method developed by us uses the principle of bio-layer Interferometry to detect IgM, IgA and IgG antibodies against SARS-CoV-2 antigens. This method overcomes many of the limitations normally faced in antibody detection by other methods and offers a superior platform for a rapid, sensitive and specific detection of SARS-CoV-2 infection. The test is economical, and the results can be obtained in as short as 30 seconds per test. In addition to its standalone use in early diagnosis of SARS-CoV-2, OnCovid total antibody assay can be used to therapeutic monitoring of antiviral therapies used in clinical management and to estimate the antibody titers during convalescent plasma donation.","Lokireddy, S. R.; Kunchala, S. R.; Godavarthy, R. P.; Kona, V. S. K.; Avula, L.; Mishra, R. K.; Nalam, M. R.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175851v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175851v1?rss=1,2020-08-17,2020-08-17,,True
64,Specific Dynamic Variations in the Peripheral Blood Lymphocyte Subsets in COVID-19 and Severe Influenza A Patients: A Retrospective Observational Study,"Background: Both COVID-19 and influenza A contribute to increased mortality among the elderly and those with existing comorbidities. Changes in the underlying immune mechanisms determine patient prognosis. This study aimed to analyze the role of lymphocyte subsets in the immunopathogenesisof COVID-19 and severe influenza A, and examined the clinical significance of their alterations in the prognosis and recovery duration. Methods: By retrospectively reviewing of patients in four groups (healthy controls, severe influenza A, non-severe COVID-19 and severe COVID-19) who were admitted to Ditan hospital between 2018 to 2020, we performed flow cytometric analysis and compared the absolute counts of leukocytes, lymphocytes, and lymphocyte subsets of the patients at different time points (weeks 1-4). Results: We reviewed the patients' data of 110 healthy blood donors, 80 Non-severe COVID-19, 19 Severe COVID-19 and 43 severe influenza A. We found total lymphocytes (0.93*109/L, 0.84*109/L vs 1.78*109/L, P < 0.0001) and lymphocyte subsets (T cells, CD4+ and CD8+ T cell subsets) of both severe patients to be significantly lower than those of healthy donors at early infection stages. Further, significant dynamic variations were observed at different time points (weeks 1-4). Conclusions: Our study indicates lymphopenia to be associated with disease severity and suggests the plausible role of lymphocyte subsets in disease progression, which in turn affects prognosis and recovery duration in patients with severe COVID-19 and influenza A.","Zhang, F.; Qian, F.; Gao, G.; Song, Y.; Xu, Y.; Wang, A.; Wang, S.; Hao, Y.; Chen, M.; Ma, X.; Zhao, T.; Guo, X.; Chen, Z.","https://www.medrxiv.org/content/10.1101/2020.08.15.20175455v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20175455v1?rss=1,2020-08-17,2020-08-17,,True
65,Evaluation of commercially available immuno-magnetic agglutination and enzyme-linked immunosorbent assays for rapid point-of-care diagnostics of COVID-19,"Introduction: Coronavirus Disease 2019 (COVID-19) is caused by severe acute respiratory coronavirus-2 (SARS-CoV-2). Fast, accurate and simple blood-based assays for quantification of anti-SARS-CoV-2 antibodies are urgently needed to identify infected individuals and keep track of the spread of disease. Methods: The study included 35 plasma samples from 22 individuals with confirmed COVID-19 by real time reverse transcriptase polymerase chain reaction and 40 non COVID-19 plasma samples. Anti-SARS-CoV-2 IgM/IgA or IgG antibodies were detected by a microfluidic quantitative immunomagnetic assay (IMA)(ViroTrack Sero COVID IgM+IgA/IgG Ab, Blusense Diagnostics, Denmark) and by enzyme-linked immunosorbent assay ((ELISA) (EuroImmun Medizinische Labordiagnostika, Germany). Results: Of the 35 plasma samples from the COVID-19 patients, 29 (82.9%) were positive for IgA/IgM or IgG by IMA and 29 samples (82.9%) were positive by ELISA. Sensitivity for only one sample per patient was 68% for IgA+IgM and 73% IgG by IMA and 73% by ELISA. For samples collected 14 days after symptom onset, the sensitivity of both IMA and ELISA was around 90%. Specificity of the IMA reached 100% compared to 95% for ELISA IgA and 97.5% for ELISA IgG. Conclusion: IMA for COVID-19 is a rapid simple-to-use point of care test with sensitivity and specificity similar to a commercial ELISA.","Moeller, M. E.; Fock, J.; Pah, P.; Veras, A. D. L. C.; Bade, M.; Donolato, M.; Israelsen, S. B.; Eugen-Olsen, J.; Benfield, T.; Engsig, F. N.","https://www.medrxiv.org/content/10.1101/2020.08.15.20172080v1?rss=1""",https://www.medrxiv.org/content/10.1101/2020.08.15.20172080v1?rss=1,2020-08-17,2020-08-17,,True
66,Sampling SARS-CoV-2 proteomes for predicted CD8 T-cell epitopes as a tool for understanding immunogenic breadth and rationale vaccine design,"Predictive models for vaccine design have become a powerful and necessary resource for the expeditiousness design of vaccines to combat the ongoing SARS-CoV-2 global pandemic. Here we use the power of these predicted models to assess the sequence diversity of circulating SARS-CoV-2 proteomes in the context of an individuals CD8 T-cell immune repertoire to identify potential. defined regions of immunogenicity. Using this approach of expedited and rational CD8 T-cell vaccine design, it may be possible to develop a therapeutic vaccine candidate with the potential for both global and local coverage.","Hare, J.; Morrison, D.; Nielsen, M.","https://www.biorxiv.org/content/10.1101/2020.08.15.250647v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.250647v1?rss=1,2020-08-16,2020-08-16,,False
67,"Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment","Virtually all SARS-CoV-2 vaccines currently in clinical testing are stored in a refrigerated or frozen state prior to use. This is a major impediment to deployment in resource-poor settings. Several use viral vectors or mRNA. In contrast to protein subunit vaccines, there is limited manufacturing expertise for these novel, nucleic acid based modalities, especially in the developing world. Neutralizing antibodies, the clearest known correlate of protection against SARS-CoV-2, are primarily directed against the Receptor Binding Domain (RBD) of the viral spike protein. We describe a monomeric, glycan engineered RBD protein fragment that is expressed at a purified yield of 200mg/L in unoptimized, mammalian cell culture and in contrast to a stabilized spike ectodomain, is tolerant of exposure to temperatures as high as 100{degrees}C when lyophilized, and upto 70{degrees}C in solution. In prime:boost guinea pig immunizations, when formulated with the MF59 like adjuvant AddaVax, the RBD derivative elicited neutralizing antibodies with an endpoint geometric mean titer of ~415 against replicative virus, comparing favourably with several vaccine formulations currently in the clinic. These features of high yield, extreme thermotolerance and satisfactory immunogenicity suggest that such RBD subunit vaccine formulations hold great promise to combat COVID-19.","Malladi, S. K.; Singh, R.; Pandey, S.; Gayathri, S.; Kanjo, K.; Ahmed, S.; Khan, M. S.; Kalita, P.; Girish, N.; Upadhyaya, A.; Reddy, P.; Pramanick, I.; Bhasin, M.; Mani, S.; Bhattacharyya, S.; Joseph, J.; Thankamani, K.; Raj, V. S.; Dutta, S.; Singh, R.; Nadig, G.; Varadarajan, R.","https://www.biorxiv.org/content/10.1101/2020.08.15.252437v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.252437v1?rss=1,2020-08-16,2020-08-16,,False
68,Susceptibility of swine cells and domestic pigs to SARS-CoV-2,"The emergence of SARS-CoV-2 has resulted in an ongoing global pandemic with significant morbidity, mortality, and economic consequences. The susceptibility of different animal species to SARS-CoV-2 is of concern due to the potential for interspecies transmission, and the requirement for pre-clinical animal models to develop effective countermeasures. In the current study, we determined the ability of SARS-CoV-2 to (i) replicate in porcine cell lines, (ii) establish infection in domestic pigs via experimental oral/intranasal/intratracheal inoculation, and (iii) transmit to co-housed naive sentinel pigs. SARS-CoV-2 was able to replicate in two different porcine cell lines with cytopathic effects. Interestingly, none of the SARS-CoV-2-inoculated pigs showed evidence of clinical signs, viral replication or SARS-CoV-2-specific antibody responses. Moreover, none of the sentinel pigs displayed markers of SARS-CoV-2 infection. These data indicate that although different porcine cell lines are permissive to SARS-CoV-2, five-week old pigs are not susceptible to infection via oral/intranasal/intratracheal challenge. Pigs are therefore unlikely to be significant carriers of SARS-CoV-2 and are not a suitable pre-clinical animal model to study SARS-CoV-2 pathogenesis or efficacy of respective vaccines or therapeutics.","Meekins, D. A.; Morozov, I.; Trujillo, J. D.; Gaudreault, N. N.; Bold, D.; Artiaga, B. L.; Indran, S. V.; Kwon, T.; Balaraman, V.; Madden, D. W.; Feldmann, H.; Henningson, J.; Ma, W.; Balasuriya, U. B. R.; Richt, J. A.","https://www.biorxiv.org/content/10.1101/2020.08.15.252395v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.252395v1?rss=1,2020-08-16,2020-08-16,,False
69,A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model,"The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019 (COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed characterization of virus-neutralizing antibodies and target epitopes is needed to understand COVID-19 pathophysiology and guide immunization strategies. Among 598 human monoclonal antibodies (mAbs) from ten COVID-19 patients, we identified 40 strongly neutralizing mAbs. The most potent mAb CV07-209 neutralized authentic SARS-CoV-2 with IC50 of 3.1 ng/ml. Crystal structures of two mAbs in complex with the SARS-CoV-2 receptor-binding domain at 2.55 and 2.70 [A] revealed a direct block of ACE2 attachment. Interestingly, some of the near-germline SARS-CoV-2 neutralizing mAbs reacted with mammalian self-antigens. Prophylactic and therapeutic application of CV07-209 protected hamsters from SARS-CoV-2 infection, weight loss and lung pathology. Our results show that non-self-reactive virus-neutralizing mAbs elicited during SARS-CoV-2 infection are a promising therapeutic strategy.","Kreye, J.; Reincke, S. M.; Kornau, H.-C.; Sanchez-Sendin, E.; Corman, V. M.; Liu, H.; Yuan, M.; Wu, N. C.; Zhu, X.; Lee, C.-C. D.; Trimpert, J.; Hoeltje, M.; Dietert, K.; Stoeffler, L.; von Wardenburg, N.; van Hoof, S.; Homeyer, M. A.; Hoffmann, J.; Abdelgawad, A.; Gruber, A. D.; Bertzbach, L. D.; Vladimirova, D.; Li, L. Y.; Barthel, P. C.; Skriner, K.; Hocke, A. C.; Hippenstiel, S.; Witzenrath, M.; Suttorp, N.; Kurth, F.; Franke, C.; Endres, M.; Schmitz, D.; Jeworowski, L. M.; Richter, A.; Schmidt, M. L.; Schwarz, T.; Mueller, M. A.; Drosten, C.; Wendisch, D.; Sander, L. E.; Osterrieder, N.; Wilson, I. A.; Pruess, H.","https://www.biorxiv.org/content/10.1101/2020.08.15.252320v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.252320v1?rss=1,2020-08-16,2020-08-16,,False
70,High titers of multiple antibody isotypes against the SARS-CoV-2 spike receptor-binding domain and nucleoprotein associate with better neutralization.,"Understanding antibody responses to SARS-CoV-2 is indispensable for the development of containment measures to overcome the current COVID-19 pandemic. Here, we determine the ability of sera from 101 recovered healthcare workers to neutralize both authentic SARS-CoV-2 and SARS-CoV-2 pseudotyped virus and address their antibody titers against SARS-CoV-2 nucleoprotein and spike receptor-binding domain. Interestingly, the majority of individuals have low neutralization capacity and only 6% of the healthcare workers showed high neutralizing titers against both authentic SARS-CoV-2 virus and the pseudotyped virus. We found the antibody response to SARS-CoV-2 infection generates antigen-specific isotypes as well as a diverse combination of antibody isotypes, with high titers of IgG, IgM and IgA against both antigens correlating with neutralization capacity. Importantly, we found that neutralization correlated with antibody titers as quantified by ELISA. This suggests that an ELISA assay can be used to determine seroneutralization potential. Altogether, our work provides a snapshot of the SARS-CoV-2 neutralizing antibody response in recovered healthcare workers and provides evidence that possessing multiple antibody isotypes may play an important role in SARS-CoV-2 neutralization.","Noval, M. G.; Kaczmarek, M. E.; Koide, A.; Rodriguez-Rodriguez, B. A.; Louie, P.; Tada, T.; Hattori, T.; Panchenko, T.; Romero, L. A.; Teng, K. W.; Bazley, A.; de Vries, M.; Samanovic, M. I.; Weiser, J. N.; Aifantis, I.; Cangiarella, J.; Mulligan, M. J.; Desvignes, L.; Dittmann, M.; Landau, N. R.; Aguero-Rosenfeld, M. E.; Koide, S.; Stapleford, K. A.","https://www.biorxiv.org/content/10.1101/2020.08.15.252353v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.252353v1?rss=1,2020-08-16,2020-08-16,,False
71,Multifractal Analysis of SARS-CoV-2 Coronavirus genomes using the wavelet transform.,"In this paper, the 1D Wavelet Transform Modulus Maxima lines (WTMM) method is used to investigate the Long-Range Correlation (LRC) and to estimate the so-called Hurst exponent of 21 isolate RNA sequence downloaded from the NCBI database of patients infected by SARS-CoV-2, Coronavirus, the Knucleotidic, Purine, Pyramidine, Ameno, Keto and GC DNA coding are used. Obtained results show the LRC character in the most sequences; except some sequences where the anti-correlated or the Classical Brownian motion character is observed. Obtained results demonstrate show that the SARS-Cov2 coronavirus undergoes mutation from a country to another or in the same country.","Ouadfeul, S.-A.","https://www.biorxiv.org/content/10.1101/2020.08.15.252411v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.252411v1?rss=1,2020-08-16,2020-08-16,,False
72,Effects of SARS-CoV-2 Mutations on Protein Structures and Intraviral Protein-Protein Interactions,"Since 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) has infected ten millions of people across the globe, and massive mutations in virus genome have occurred during the rapid spread of this novel coronavirus. Variance in protein sequence might lead to change in protein structure and interaction, then further affect the viral physiological characteristics, which could bring tremendous influence on the pandemic. In this study, we investigated 18 non-synonymous mutations in SARS-CoV-2 genome which incidence rates were all [&ge;]1% as of July 15th, 2020, then modeled the mutated protein structures and compared them with the reference ones. The results showed that four types of mutations could cause dramatic changes in protein structures (RMSD [&ge;]5.0 [A]), which were Q57H and G251V in open reading frames 3a (ORF3a), S194L and R203K/G204R in nucleocapsid (N). Next, we found that these mutations could affect the binding affinity of intraviral protein interactions. In addition, the hot spots within these docking complexes were altered, among which the mutation Q57H was involved in both Orf3a-Orf8 and Orf3a-S protein interactions. Besides, these mutations were widely distributed all over the world, and their occurrences fluctuated as time went on. Notably, the incidences of R203K/G204R in N and Q57H in Orf3a were both over 50% in some countries. Overall, our findings suggest that SARS-CoV-2 mutations can change viral protein structure, binding affinity and hot spots of the interface, thereby may have impacts on SARS-CoV-2 transmission, diagnosis and treatment of COVID-19.","Wu, S.; Tian, C.; Liu, P.; Guo, D.; Zheng, W.; Huang, X.; Zhang, Y.; Liu, L.","https://www.biorxiv.org/content/10.1101/2020.08.15.241349v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.15.241349v1?rss=1,2020-08-16,2020-08-16,,False
73,Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro,"The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the current pandemic, coronavirus disease 2019 (COVID-19), has taken a huge toll on human lives and the global economy. Therefore, effective treatments against this disease are urgently needed. Here, we established a fluorescence resonance energy transfer (FRET)-based high-throughput screening platform to screen compound libraries to identify drugs targeting the SARS-CoV-2 main protease (Mpro), in particular those which are FDA-approved, to be used immediately to treat patients with COVID-19. Mpro has been shown to be one of the most important drug targets among SARS-related coronaviruses as impairment of Mpro blocks processing of viral polyproteins which halts viral replication in host cells. Our findings indicate that the anti-malarial drug tafenoquine (TFQ) induces significant conformational change in SARS-CoV-2 Mpro and diminishes its protease activity. Specifically, TFQ reduces the -helical content of Mpro, which converts it into an inactive form. Moreover, TFQ greatly inhibits SARS-CoV-2 infection in cell culture system. Hence, the current study provides a mechanistic insight into the mode of action of TFQ against SARS-CoV-2 Mpro. Moreover, the low clinical toxicity of TFQ and its strong antiviral activity against SARS-CoV-2 should warrant further testing in clinical trials.","Chen, Y.; Yang, W.-H.; Huang, L.-M.; Wang, Y.-C.; Yang, C.-S.; Liu, Y.-L.; Hou, M.-H.; Tsai, C.-L.; Chou, Y.-Z.; Huang, B.-Y.; Hung, C.-F.; Hung, Y.-L.; Chen, J.-S.; Chiang, Y.-P.; Cho, D.-Y.; Jeng, L.-B.; Tsai, C.-H.; Hung, M.-C.","https://www.biorxiv.org/content/10.1101/2020.08.14.250258v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.250258v1?rss=1,2020-08-15,2020-08-15,,False
74,In plain sight: the role of alpha-1-antitrypsin in COVID-19 pathogenesis and therapeutics.,"Entry of SARS-CoV-2 is facilitated by endogenous and exogenous proteases. These proteases proteolytically activate the SARS-CoV-2 spike glycoprotein and are key modulators of virus tropism. We show that SARS-CoV-2 naive serum exhibits significant inhibition of SARS-CoV-2 entry. We identify alpha-1-antitrypsin (AAT) as the major serum protease inhibitor that potently restrict protease-mediated entry of SARS-CoV-2. AAT inhibition of protease-mediated SARS-CoV-2 entry in vitro occurs at concentrations far below what is present in serum and bronchoalveolar tissues, suggesting that AAT effects are physiologically relevant. Moreover, AAT deficiency affects up to 20% of the population and its symptomatic manifestations coincides with many risk factors associated with severe COVID-19 disease. In addition to the effects that AAT may have on viral entry itself, we argue that the anti-inflammatory and coagulation regulatory activity of AAT have implications for coronavirus disease 2019 (COVID-19) pathogenicity, SARS-CoV-2 tissue restriction, convalescent plasma therapies, and even potentially AAT therapy.","Oguntuyo, K. Y.; Stevens, C. S.; Siddiquey, M. N.; Schilke, R. M.; Woolard, M. D.; Zhang, H.; Acklin, J. A.; Ikegame, S.; Hung, C.-t.; Lim, J. K.; Cross, R. W.; Geisbert, T. W.; Ivanov, S. S.; Kamil, J. P.; Lee, B.","https://www.biorxiv.org/content/10.1101/2020.08.14.248880v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.248880v1?rss=1,2020-08-15,2020-08-15,,False
75,SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry,"The recently emerged pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly, leading to a global COVID-19 pandemic. Binding of the viral spike protein (SARS-2-S) to cell surface receptor angiotensin-converting enzyme 2 (ACE2) mediates host cell infection. In the present study, we demonstrate that in addition to ACE2, the S1 subunit of SARS-2-S binds to HDL and that SARS-CoV-2 hijacks the SR-B1-mediated HDL uptake pathway to facilitate its entry. SR-B1 facilitates SARS-CoV-2 entry into permissive cells by augmenting virus attachment. MAb (monoclonal antibody)-mediated blocking of SARS-2-S-HDL binding and SR-B1 antagonists strongly inhibit HDL-enhanced SARS-CoV-2 infection. Notably, SR-B1 is co-expressed with ACE2 in human pulmonary and extrapulmonary tissues. These findings revealed a novel mechanism for SARS-CoV-2 entry and could provide a new target to treat SARS-CoV-2 infection.","Wei, C.; Wan, L.; Yan, Q.; Wang, X.; Zhang, J.; Zhang, Y.; Sun, J.; Yang, X.; Gong, J.; Fan, C.; Yang, X.; Wang, Y.; Wang, X.; Li, J.; Yang, H.; Li, H.; Zhang, Z.; Wang, R.; Du, P.; Zong, Y.; Yin, F.; Zhang, W.; Peng, Y.; Lin, H.; Zhang, R.; Chen, W.; Gao, Q.; Cao, Y.; Zhong, H.","https://www.biorxiv.org/content/10.1101/2020.08.13.248872v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.248872v1?rss=1,2020-08-14,2020-08-14,,False
76,Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography,"The genome of the SARS-CoV-2 coronavirus contains 29 proteins, of which 15 are nonstructural. Nsp10 and Nsp16 form a complex responsible for the capping of mRNA at the 5' terminus. In the methylation reaction the S-adenosyl-L-methionine serves as the donor of the methyl group that is transferred to Cap-0 at the first transcribed nucleotide to create Cap-1. The presence of Cap-1 makes viral RNAs mimic the host transcripts and prevents their degradation. To investigate the 2'-O methyltransferase activity of SARS-CoV-2 Nsp10/16, we applied fixed-target serial synchrotron crystallography (SSX) which allows for physiological temperature data collection from thousands of crystals, significantly reducing the x-ray dose while maintaining a biologically relevant temperature. We determined crystal structures of Nsp10/16 that revealed the states before and after the methylation reaction, for the first time illustrating coronavirus Nsp10/16 complexes with the m7GpppAm2'-O Cap-1, where 2'OH of ribose is methylated. We compare these structures with structures of Nsp10/16 at 297 K and 100 K collected from a single crystal. This data provide important mechanistic insight and can be used to design small molecules that inhibit viral RNA maturation making SARS-CoV-2 sensitive to host innate response.","Wilamowski, M.; Sherrell, D.; Minasova, G.; Kim, Y.; Shuvaloca, L.; Lavens, A.; Chard, R.; Maltseva, N.; Jedrzejczak, R.; Rosas-Lemus, M.; Saint, N.; Foster, I. T.; Michalska, K.; Satchell, K. J.; Joachimiak, A.","https://www.biorxiv.org/content/10.1101/2020.08.14.251421v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.251421v1?rss=1,2020-08-14,2020-08-14,,False
77,Pandemic danger to the deep: the risk of marine mammals contracting SARS-CoV-2 from wastewater,"We are in unprecedented times with the ongoing COVID-19 pandemic. The pandemic has impacted public health, the economy and our society on a global scale. In addition, the impacts of COVID-19 permeate into our environment and wildlife as well. Here, we discuss the essential role of wastewater treatment and management during these times. A consequence of poor wastewater management is the discharge of untreated wastewater carrying infectious SARS-CoV-2 into natural water systems that are home to marine mammals. Here, we predict the susceptibility of marine mammal species using a modelling approach. Many species of whale, dolphin and seal, as well as otters, are predicted to be highly susceptible to infection by the SARS-CoV-2 virus. In addition, geo-mapping highlights how current wastewater management in Alaska may lead to susceptible marine mammal populations being exposed to the virus. Since over half of these susceptibility species are already at risk worldwide, the release of the virus via untreated wastewater could have devastating consequences for their already declining populations. For these reasons, we discuss approaches that can be taken by the public, policymakers and wastewater treatment facilities to reduce the risk of virus spillover in our natural water systems. Thus, we highlight the potential for reverse zoonotic transmission of COVID-19 and its impact on marine wildlife; impacts that can be mitigated with appropriate action to prevent further damage to these vulnerable populations.","Mathavarajah, S.; Stoddart, A. K.; Gagnon, G. A.; Dellaire, G.","https://www.biorxiv.org/content/10.1101/2020.08.13.249904v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.249904v1?rss=1,2020-08-14,2020-08-14,,False
78,"SARS-CoV-2 Infection And Longitudinal Fecal Screening In Malayan Tigers (Panthera tigris jacksoni), Amur Tigers (Panthera tigris altaica), And African Lions (Panthera leo krugeri) At The Bronx Zoo, New York, USA","Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) emerged as the cause of a global pandemic in 2019-2020. In March 2020 New York City became the USA epicenter for the pandemic. On March 27, 2020 a Malayan tiger (Panthera tigris jacksoni) at the Bronx Zoo in New York City developed a cough and wheezing with subsequent inappetence. Over the next week, an additional Malayan tiger and two Amur tigers (P. t. altaica) in the same building and three lions (Panthera leo krugeri) in a separate building also became ill. The index case was immobilized, and physical examination and bloodwork results were unremarkable. Thoracic radiography and ultrasonography revealed peribronchial cuffing with bronchiectasis, and mild lung consolidation with alveolar-interstitial syndrome, respectively. SARS-CoV-2 RNA was identified by real-time, reverse transcriptase PCR (rRT-PCR) on oropharyngeal and nasal swabs and tracheal wash fluid. Cytologic examination of tracheal wash fluid revealed necrosis, and viral RNA was detected in necrotic cells by in situ hybridization, confirming virus-associated tissue damage. SARS-CoV-2 was isolated from the tracheal wash fluid of the index case, as well as the feces from one Amur tiger and one lion. Fecal viral RNA shedding was confirmed in all seven clinical cases and an asymptomatic Amur tiger. Respiratory signs abated within 1-5 days for most animals, though persisted intermittently for 16 days in the index case. Fecal RNA shedding persisted for as long as 35 days beyond cessation of respiratory signs. This case series describes the clinical presentation, diagnostic evaluation, and management of tigers and lions infected with SARS-CoV-2, and describes the duration of viral RNA fecal shedding in these cases. This report documents the first known natural transmission of SARS-CoV-2 from humans to animals in the USA, and is the first report of SARS-CoV-2 in non-domestic felids.","Bartlett, S. L.; Diel, D. G.; Wang, L.; Zec, S.; Laverack, M.; Martins, M.; Caserta, L. C.; Killian, M. L.; Terio, K.; Olmstead, C.; Delaney, M. A.; Stokol, T.; Ivancic, M.; Jenkins-Moore, M.; Ingerman, K.; Teegan, T.; McCann, C.; Thomas, P.; McAloose, D.; Sykes, J. M.; Calle, P. P.","https://www.biorxiv.org/content/10.1101/2020.08.14.250928v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.250928v1?rss=1,2020-08-14,2020-08-14,,False
79,Extensive Genetic Diversity and Host Range of Rodent-borne Coronaviruses,"To better understand the genetic diversity, host association and evolution of coronaviruses (CoVs) in China we analyzed a total of 696 rodents encompassing 16 different species sampled from Zhejiang and Yunnan provinces. Based on the reverse transcriptase PCR-based CoV screening CoVs of fecal samples and subsequent sequence analysis of the RdRp gene, we identified CoVs in diverse rodent species, comprising Apodemus agrarius, Apodemus latronum, Bandicota indica, Eothenomys miletus, E. eleusis, Rattus andamanesis, Rattus norvegicus, and R. tanezumi. Apodemus chevrieri was a particularly rich host, harboring 25 rodent CoVs. Genetic and phylogenetic analysis revealed the presence of three groups of CoVs carried by a range of rodents that were closely related to the Lucheng Rn rat coronavirus (LRNV), China Rattus coronavirus HKU24 (ChRCoV_HKU24) and Longquan Rl rat coronavirus (LRLV) identified previously. One newly identified A. chevrieri-associated virus closely related to LRNV lacked an NS2 gene. This virus had a similar genetic organization to AcCoV-JC34, recently discovered in the same rodent species in Yunnan, suggesting that it represents a new viral subtype. Notably, additional variants of LRNV were identified that contained putative nonstructural NS2b genes located downstream of the NS2 gene that were likely derived from the host genome. Recombination events were also identified in the ORF1a gene of Lijiang-71. In sum, these data reveal the substantial genetic diversity and genomic complexity of rodent-borne CoVs, and greatly extend our knowledge of these major wildlife virus reservoirs.","Wang, W.; Lin, X.-D.; Zhang, H.-L.; Wang, M.-R.; Guan, X.-Q.; Holmes, E. C.; Zhang, Y.-Z.","https://www.biorxiv.org/content/10.1101/2020.08.11.245415v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.245415v1?rss=1,2020-08-14,2020-08-14,,False
80,Differential methylation as a mediator of COVID-19 susceptibility,"The COVID-19 outbreak shows a huge variation in prevalence and mortality on geographical level but also within populations1. The ACE2 gene, identified as the SARS-CoV2 receptor, has been shown to facilitate the viral invasion and people with higher ACE2 expression generally are more severely affected2, 3. As there is a lot of variability in ACE2 expression between individuals we hypothesized that differential DNA methylation profiles could be (one of) the confounding factors explaining this variability. Here we show that epigenetic profiling of host tissue, especially in the ACE2 promoter region and its homologue ACE1, may be important risk factors for COVID-19. Our results propose that variable methylation can explain (part of) the differential susceptibility, symptom severity and death rate for COVID-19. Our findings are a promising starting point to further evaluate the potential of ACE1/2 methylation and other candidates as a predictor for clinical outcome upon SARS-CoV2 infection.","Steyaert, S.; Trooskens, G.; Delanghe, J. R.; Van Criekinge, W.","https://www.biorxiv.org/content/10.1101/2020.08.14.251538v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.251538v1?rss=1,2020-08-14,2020-08-14,,False
81,Metaviromic identification of genetic hotspots of coronavirus pathogenicity using machine learning,"The COVID-19 pandemic caused by SARS-CoV-2 has become a major threat across the globe. Here, we developed machine learning approaches to identify key pathogenic regions in coronavirus genomes. We trained and evaluated 7,562,625 models on 3,665 genomes including SARS-CoV-2, MERS-CoV, SARS-CoV and other coronaviruses of human and animal origins to return quantitative and biologically interpretable signatures at nucleotide and amino acid resolutions. We identified hotspots across the SARS-CoV-2 genome including previously unappreciated features in spike, RdRp and other proteins. Finally, we integrated pathogenicity genomic profiles with B cell and T cell epitope predictions for enrichment of sequence targets to help guide vaccine development. These results provide a systematic map of predicted pathogenicity in SARS-CoV-2 that incorporates sequence, structural and immunological features, providing an unbiased collection of genetic elements for functional studies. This metavirome-based framework can also be applied for rapid characterization of new coronavirus strains or emerging pathogenic viruses.","Park, J. J.; Chen, S.","https://www.biorxiv.org/content/10.1101/2020.08.13.248575v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.248575v1?rss=1,2020-08-14,2020-08-14,,False
82,Furin cleavage of SARS-CoV-2 Spike promotes but is not essential for infection and cell-cell fusion,"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects cells by binding to the host cell receptor Ace2 and undergoing virus-host membrane fusion. Fusion is triggered by the protease TMPRSS2, which processes the viral Spike (S) protein to reveal the fusion peptide. SARS-CoV-2 has evolved a multibasic site at the S1-S2 boundary, which is thought to be cleaved by furin in order to prime S protein for TMPRSS2 processing. Here we show that CRISPR-Cas9 knockout of furin reduces, but does not prevent, the production of infectious SARS-CoV-2 virus. Comparing S processing in furin knockout cells to multibasic site mutants reveals that while loss of furin substantially reduces S1-S2 cleavage it does not prevent it. SARS-CoV-2 S protein also mediates cell-cell fusion, potentially allowing virus to spread virion-independently. We show that loss of furin in either donor or acceptor cells reduces, but does not prevent, TMPRSS2-dependent cell-cell fusion, unlike mutation of the multibasic site that completely prevents syncytia formation. Our results show that while furin promotes both SARS-CoV-2 infectivity and cell-cell spread it is not essential, suggesting furin inhibitors will not prevent viral spread.","Papa, G.; Mallery, D.; Albecka, A.; Welch, L.; Cattin-Ortola, J.; Luptak, J.; Paul, D.; McMahon, H.; Goodfellow, I. G.; Carter, A. P.; Munro, S. P.; James, L. C.","https://www.biorxiv.org/content/10.1101/2020.08.13.243303v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.243303v1?rss=1,2020-08-14,2020-08-14,,False
83,Immunoreactive peptide maps of SARS-CoV-2 and other human coronaviruses,"Serodiagnosis of SARS-CoV-2 infection is impeded by immunological cross-reactivity to the human coronaviruses (HCoV) SARS-CoV-2, SARS-CoV-1, MERS-CoV, OC43, 229E, HKU1, and NL63. Here we report the identification of humoral immune responses to SARS-CoV-2 and other HCoV peptides that can be used to detect asymptomatic, mild and, severe SARS-CoV-2 infections, and may enable the discovery of biomarkers for immunity following infection or vaccination.","Mishra, N.; Huang, X.; Joshi, S.; Guo, C.; Ng, J.; Thakkar, R.; Wu, Y.; Dong, X.; Li, Q.; Pinapati, R.; Sullivan, E.; Caciula, A.; Tokarz, R.; Briese, T.; Lu, J.; Lipkin, W. I.","https://www.biorxiv.org/content/10.1101/2020.08.13.249953v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.249953v1?rss=1,2020-08-14,2020-08-14,,False
84,Open Science Saves Lives: Lessons from the COVID-19 Pandemic,"In the last decade Open Science principles, such as Open Access, study preregistration, use of preprints, making available data and code, and open peer review, have been successfully advocated for and are being slowly adopted in many different research communities. In response to the COVID-19 pandemic many publishers and researchers have sped up their adoption of some of these Open Science practices, sometimes embracing them fully and sometimes partially or in a sub-optimal manner. In this article, we express concerns about the violation of some of the Open Science principles and its potential impact on the quality of research output. We provide evidence of the misuses of these principles at different stages of the scientific process. We call for a wider adoption of Open Science practices in the hope that this work will encourage a broader endorsement of Open Science principles and serve as a reminder that science should always be a rigorous process, reliable and transparent, especially in the context of a pandemic where research findings are being translated into practice even more rapidly. We provide all data and scripts at https://osf.io/renxy/.","Besancon, L.; Peiffer-Smadja, N.; Segalas, C.; Jiang, H.; Masuzzo, P.; Smout, C. A.; Deforet, M.; Leyrat, C.","https://www.biorxiv.org/content/10.1101/2020.08.13.249847v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.249847v1?rss=1,2020-08-14,2020-08-14,,False
85,Tissue-resident memory CD8 T-cell responses elicited by a single injection of a multi-target COVID-19 vaccine,"The COVID-19 pandemic is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which enters the body principally through the nasal and larynx mucosa and progress to the lungs through the respiratory tract. SARS-CoV-2 replicates efficiently in respiratory epithelial cells motivating the development of alternative and rapidly scalable vaccine inducing mucosal protective and long-lasting immunity. We have previously developed an immunologically optimized multi-neoepitopes-based peptide vaccine platform which has already demonstrated tolerance and efficacy in hundreds of lung cancer patients. Here, we present a multi-target CD8 T cell peptide COVID-19 vaccine design targeting several structural (S, M, N) and non-structural (NSPs) SARS-CoV-2 proteins with selected epitopes in conserved regions of the SARS-CoV-2 genome. We observed that a single subcutaneous injection of a serie of epitopes induces a robust immunogenicity in-vivo as measured by IFN{gamma} ELIspot. Upon tetramer characterization we found that this serie of epitopes induces a strong proportion of virus-specific CD8 T cells expressing CD103, CD44, CXCR3 and CD49a, the specific phenotype of tissue-resident memory T lymphocytes (Trm). Finally, we observed broad cellular responses, as characterized by IFN{gamma} production, upon restimulation with structural and non-structural protein-derived epitopes using blood T cells isolated from convalescent asymptomatic, moderate and severe COVID-19 patients. These data provide insights for further development of a second generation of COVID-19 vaccine focused on inducing lasting Th1-biased memory CD8 T cell sentinels protection using immunodominant epitopes naturally observed after SARS-CoV-2 infection resolution.

Statement of SignificanceHumoral and cellular adaptive immunity are different and complementary immune defenses engaged by the body to clear viral infection. While neutralizing antibodies have the capacity to block virus binding to its entry receptor expressed on human cells, memory T lymphocytes have the capacity to eliminate infected cells and are required for viral clearance. However, viruses evolve quickly, and their antigens are prone to mutations to avoid recognition by the antibodies (phenomenon named  antigenic drift). This limitation of the antibody-mediated immunity could be addressed by the T-cell mediated immunity, which is able to recognize conserved viral peptides from any viral proteins presented by virus-infected cells. Thus, by targeting several proteins and conserved regions on the genome of a virus, T-cell epitope-based vaccines are less subjected to mutations and may work effectively on different strains of the virus. We designed a multi-target T cell-based vaccine containing epitope regions optimized for CD8+ T cell stimulation that would drive long-lasting cellular immunity with high specificity, avoiding undesired effects such as antibody-dependent enhancement (ADE) and antibody-induced macrophages hyperinflammation that could be observed in subjects with severe COVID-19. Our in-vivo results showed that a single injection of selected CD8 T cell epitopes induces memory viral-specific T-cell responses with a phenotype of tissue-resident memory T cells (Trm). Trm has attracted a growing interest for developing vaccination strategies since they act as immune sentinels in barrier tissue such as the respiratory tract and the lung. Because of their localization in tissues, they are able to immediately recognize infected cells and, because of their memory phenotypes, they rapidly respond to viral infection by orchestrating local protective immune responses to eliminate pathogens. Lastly, such multiepitope-based vaccination platform uses robust and well-validated synthetic peptide production technologies that can be rapidly manufactured in a distributed manner.","Gauttier, V.; Morello, A.; Girault, I.; Mary, C.; Belarif, L.; Desselle, A.; Wilhelm, E.; Bourquard, T.; Pengam, S.; Teppaz, G.; Thepenier, V.; Biteau, K.; De Barbeyrac, E.; Kiepferle, D.; Vasseur, B.; Le Flem, F.-X.; Debieuvre, D.; Costantini, D.; Poirier, N.","https://www.biorxiv.org/content/10.1101/2020.08.14.240093v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.240093v1?rss=1,2020-08-14,2020-08-14,,False
86,In Silico Design of siRNAs Targeting Existing and Future Respiratory Viruses with VirusSi,"The COVID-19 pandemic has exposed global inadequacies in therapeutic options against both the COVID-19-causing SARS-CoV-2 virus and other newly emerged respiratory viruses. In this study, we present the VirusSi computational pipeline, which facilitates the rational design of siRNAs to target existing and future respiratory viruses. Mode A of VirusSi designs siRNAs against an existing virus, incorporating considerations on siRNA properties, off-target effects, viral RNA structure and viral mutations. It designs multiple siRNAs out of which the top candidate targets >99% of SARS-CoV-2 strains, and the combination of the top four siRNAs is predicted to target all SARS-CoV-2 strains. Additionally, we develop Greedy Algorithm with Redundancy (GAR) and Similarity-weighted Greedy Algorithm with Redundancy (SGAR) to support the Mode B of VirusSi, which pre-designs siRNAs against future emerging viruses based on existing viral sequences. Time-simulations using known coronavirus genomes as early as 10 years prior to the COVID-19 outbreak show that at least three SARS-CoV-2-targeting siRNAs are among the top 30 pre-designed siRNAs. Before-the-outbreak pre-design is also possible against the MERS-CoV virus and the 2009-H1N1 swine flu virus. Our data support the feasibility of pre-designing anti-viral siRNA therapeutics prior to viral outbreaks. We propose the development of a collection of pre-designed, safety-tested, and off-the-shelf siRNAs that could accelerate responses toward future viral diseases.","Zhang, D.; Lu, J.","https://www.biorxiv.org/content/10.1101/2020.08.13.250076v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.250076v1?rss=1,2020-08-14,2020-08-14,,False
87,Hydroxychloroquine: mechanism of action inhibiting SARS-CoV2 entry.,"BackgroundSARS-coronavirus 2 (SARS-CoV-2) is currently causing a worldwide pandemic. Potential drugs identified for the treatment of SARS-CoV-2 infection include chloroquine (CQ), its derivative hydroxychloroquine (HCQ), and the anesthetic propofol. Their mechanism of action in SARS-CoV-2 infection is poorly understood. Recently, anesthetics, both general and local, were shown to disrupt ordered lipid domains. These same lipid domains recruit the SARS-CoV-2 surface receptor angiotensin converting enzyme 2 (ACE2) to an endocytic entry point and their disruption by cholesterol depletion decreases ACE2 recruitment and viral entry.

MethodsViral entry was determined using a SARS-CoV-2 pseudovirus (SARS2-PV) and a luciferase reporter gene expressed by the virus after treatment of the cells with 50 M propofol, tetracaine, HCQ, and erythromycin. HCQ disruption of monosialotetrahexosylganglioside1 (GM1) lipid rafts, phosphatidylinositol 4,5-bisphosphate (PIP2) domains, and ACE2 receptor at nanoscale distances was monitored by direct stochastic reconstruction microscopy (dSTORM). Cells were fixed, permeabilized, and then labeled with either fluorescent cholera toxin B (CTxB) or antibody and then fixed again prior to imaging. Cluster analysis of dSTORM images was used to determine size and number and cross pair correlation was used to determine trafficking of endogenously expressed ACE2 in and out of lipid domains.

ResultsPropofol, tetracaine, and HCQ inhibit SARS2-PV viral entry. HCQ directly perturbs both GM1 lipid rafts and PIP2 domains. GM1 rafts increased in size and number similar to anesthetic disruption of lipid rafts; PIP2 domains decreased in size and number. HCQ blocked both GM1 and PIP2 domains ability to attract and cluster ACE2.

ConclusionsWe conclude HCQ is an anesthetic-like compound that disrupts GM1 lipid rafts similar to propofol and other local or general anesthetics. Furthermore, we conclude disruption of GM1 raft function, and not the concentration of GM1 raft molecules, governs the antiviral properties of HCQ. HCQ disruption of the membrane appears to also disrupt the production of host defense peptide, hence an antimicrobial such as erythromycin could be an important combined treatment. Nonetheless erythromycin has anti-SARS-CoV-2 activity and may combine with HCQ to reduce infection.

KEY POINTSQuestion: What is the molecular basis for antiviral activity of hydroxychloroquine and propofol?

Findings: Hydroxychloroquine disrupt lipid rafts similar to local and general anesthetics.

Meaning: Since lipids cluster ACE2 and facilitate viral entry, hydroxychloroquine and anesthetics appear to inhibit viral entry by disrupting the lipid clustering and ACE2 localization.","Yuan, Z.; Pavel, M. A.; Wang, H.; Hansen, S.","https://www.biorxiv.org/content/10.1101/2020.08.13.250217v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.250217v1?rss=1,2020-08-14,2020-08-14,,False
88,Designed Variants of Recombinant ACE2-Fc that Decouple Anti-SARS-CoV-2 Activities from Unwanted Cardiovascular Effects,"Angiotensin-converting enzyme 2 (ACE2) is the entry receptor for SARS-CoV-2, and recombinant ACE2 decoys are being evaluated as new antiviral therapies. We designed and tested an ACE2-Fc fusion protein, which has the benefits of a long pharmacological half-life and the potential to facilitate immune clearance of the virus. Out of the concern that the intrinsic catalytic activity of ACE2 may unintentionally alter the balance of its hormonal substrates and cause adverse cardiovascular effects in treatment, we performed a mutagenesis screening for inactivating the enzyme. Three mutants, R273A, H378A and E402A, completely lost their enzymatic activity for either surrogate or physiological substrates. All of them remained capable of binding SARS-CoV-2 and could suppress the transduction of a pseudotyped virus in cell culture. This study established new ACE2-Fc candidates as antiviral treatment for SARS-CoV-2 without potentially harmful side effects from ACE2s catalytic actions toward its vasoactive substrates.","Liu, P.; Xie, X.; Gao, L.; Jin, J.","https://www.biorxiv.org/content/10.1101/2020.08.13.248351v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.248351v1?rss=1,2020-08-14,2020-08-14,,False
89,"Ex vivo detection of SARS-CoV-2-specific CD8+ T cells: rapid induction, prolonged contraction, and formation of functional memory","CD8+ T cells are critical for the elimination and long-lasting protection of many viral infections, but their role in the current SARS-CoV-2 pandemic is unclear. Emerging data indicates that SARS-CoV-2-specific CD8+ T cells are detectable in the majority of individuals recovering from SARS-CoV-2 infection. However, optimal virus-specific epitopes, the role of pre-existing heterologous immunity as well as their kinetics and differentiation program during disease control have not been defined in detail. Here, we show that both pre-existing and newly induced SARS-CoV-2-specific CD8+ T-cell responses are potentially important determinants of immune protection in mild SARS-CoV-2 infection. In particular, our results can be summarized as follows: First, immunodominant SARS-CoV-2-specific CD8+ T-cell epitopes are targeted in the majority of individuals with convalescent SARS-CoV-2 infection. Second, MHC class I tetramer analyses revealed the emergence of phenotypically diverse and functionally competent pre-existing and newly induced SARS-CoV-2-specific memory CD8+ T cells that showed similar characteristics compared to influenza-specific CD8+ T cells. Third, SARS-CoV-2-specific CD8+ T-cell responses are more robustly detectable than antibodies against the SARS-CoV-2-spike protein. This was confirmed in a longitudinal analysis of acute-resolving infection that demonstrated rapid induction of the SARS-CoV-2-specific CD8+ T cells within a week followed by a prolonged contraction phase that outlasted the waning humoral immune response indicating that CD8+ T-cell responses might serve as a more precise correlate of antiviral immunity than antibody measurements after convalescence. Collectively, these data provide new insights into the fine specificity, heterogeneity, and dynamics of SARS-CoV-2-specific memory CD8+ T cells, potentially informing the rational development of a protective vaccine against SARS-CoV-2.","Schulien, I.; Kemming, J.; Oberhardt, V.; Wild, K.; Seidel, L. M.; Killmer, S.; Sagar,; Daul, F.; Salvat Lago, M.; Decker, A.; Luxenburger, H.; Binder, B.; Bettinger, D.; Sogukpinar, O.; Rieg, S.; Panning, M.; Huzly, D.; Schwemmle, M.; Kochs, G.; Waller, C. F.; Nieters, A.; Duerschmied, D.; Emmerich, F.; Mei, H.; Schulz, A.; Llewellyn-Lacey, S.; Price, D. A.; Boettler, T.; Bengsch, B.; Thimme, R.; Hofmann, M.; Neumann-Haefelin, C.","https://www.biorxiv.org/content/10.1101/2020.08.13.249433v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.13.249433v1?rss=1,2020-08-14,2020-08-14,,False
90,Methylene Blue has a potent antiviral activity against SARS-CoV-2 in the absence of UV-activation in vitro,"Methylene blue is an FDA and EMA approved drug with an excellent safety profile. It displays broad-spectrum virucidal activity in the presence of UV light and has been shown to be effective in inactivating various viruses in blood products prior to transfusions. In addition, its use has been validated for methemoglobinemia and malaria treatment. Here we show the virucidal activity of methylene blue at low micromolar concentrations and in the absence of UV activation against SARS-CoV2.","Cagno, V.; Medaglia, C.; Cerny, A.; Cerny, T.; Tapparel, C.; Cerny, E.","https://www.biorxiv.org/content/10.1101/2020.08.14.251090v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.251090v1?rss=1,2020-08-14,2020-08-14,,False
91,"Discovery of Clioquinol and Analogues as Novel Inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection, ACE2 and ACE2 - Spike Protein Interaction In Vitro","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. Here in, we discovered Clioquinol (5-chloro-7-iodo-8-quinolinol (CLQ)), a FDA approved drug and two of its analogues (7-bromo-5-chloro-8-hydroxyquinoline (CLBQ14); and 5, 7-Dichloro-8-hydroxyquinoline (CLCQ)) as potent inhibitors of SARS-CoV-2 infection induced cytopathic effect in vitro. In addition, all three compounds showed potent anti-exopeptidase activity against recombinant human angiotensin converting enzyme 2 (rhACE2) and inhibited the binding of rhACE2 with SARS-CoV-2 Spike (RBD) protein. CLQ displayed the highest potency in the low micromolar range, with its antiviral activity showing strong correlation with inhibition of rhACE2 and rhACE2-RBD interaction. Altogether, our findings provide a new mode of action and molecular target for CLQ and validates this pharmacophore as a promising lead series for clinical development of potential therapeutics for COVID-19.","Olaleye, O. A.; Kaur, M.; Onyenaka, C. C.; Adebusuyi, T. O.","https://www.biorxiv.org/content/10.1101/2020.08.14.250480v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.250480v1?rss=1,2020-08-14,2020-08-14,,False
92,Rational Design of SARS-CoV-2 Spike Glycoproteins To Increase Immunogenicity By T Cell Epitope Engineering,"The current COVID-19 pandemic caused by SARS-CoV-2 has resulted in millions of confirmed cases and thousands of deaths globally. Extensive efforts and progress have been made to develop effective and safe vaccines against COVID-19. A primary target of these vaccines is the SARS-CoV-2 spike (S) protein, and many studies utilized structural vaccinology techniques to either stabilize the protein or fix the receptor-binding domain at certain states. In this study, we extended an evolutionary protein design algorithm, EvoDesign, to create thousands of stable S protein variants without perturbing the surface conformation and B cell epitopes of the S protein. We then evaluated the mutated S protein candidates based on predicted MHC-II T cell promiscuous epitopes as well as the epitopes similarity to human peptides. The presented strategy aims to improve the S proteins immunogenicity and antigenicity by inducing stronger CD4 T cell response while maintaining the proteins native structure and function. The top EvoDesign S protein candidate (Design-10705) recovered 31 out of 32 MHC-II T cell promiscuous epitopes in the native S protein, in which two epitopes were present in all seven human coronaviruses. This newly designed S protein also introduced nine new MHC-II T cell promiscuous epitopes and showed high structural similarity to its native conformation. The proposed structural vaccinology method provides an avenue to rationally design the antigens structure with increased immunogenicity, which could be applied to the rational design of new COVID-19 vaccine candidates.","Ong, E.; Huang, X.; Pearce, R.; Zhang, Y.; He, Y.","https://www.biorxiv.org/content/10.1101/2020.08.14.251496v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.251496v1?rss=1,2020-08-14,2020-08-14,,False
93,SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2,"Antiviral therapeutics against SARS-CoV-2 are needed to treat the pandemic disease COVID-19. Pharmacological targeting of a host factor required for viral replication can suppress viral spread with a low probability of viral mutation leading to resistance. Here, we performed a genome-wide screen in human lung epithelial cells to identify potential host therapeutic targets. We report that the kinase SRPK1, together with the closely related SRPK2, are jointly essential for SARS-CoV-2 replication; inhibition of SRPK1/2 with small molecules led to a dramatic decrease (more than 100,000-fold) in SARS-CoV-2 virus production in immortalized and primary human lung cells. Subsequent biochemical studies revealed that SPRK1/2 phosphorylate the viral nucleocapsid (N) protein at sites highly conserved across human coronaviruses and, due to this conservation, even a distantly related coronavirus was highly sensitive to an SPRK1/2 inhibitor. Together, these data suggest that SRPK1/2-targeted therapies may be an efficacious strategy to prevent or treat COVID-19 and other coronavirus-mediated diseases.","Heaton, B. E.; Trimarco, J. D.; Hamele, C. E.; Harding, A. T.; Tata, A.; Zhu, X.; Tata, P. R.; Smith, C. M.; Heaton, N. S.","https://www.biorxiv.org/content/10.1101/2020.08.14.251207v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.14.251207v1?rss=1,2020-08-14,2020-08-14,,False
94,Ambroxol and Ciprofloxacin Show Activity Against SARS-CoV2 in Vero E6 Cells at Clinically-Relevant Concentrations,"We studied the activity of a range of weakly basic and moderately lipophilic drugs against SARS CoV2 in Vero E6 cells, using Vero E6 survival, qPCR of viral genome and plaque forming assays. No clear relationship between their weakly basic and hydrophobic nature upon their activity was observed. However, the approved drugs ambroxol and ciprofloxacin showed potent activity at concentrations that are clinically relevant and within their known safety profiles, and so may provide potentially useful agents for preclinical and clinical studies in COVID-19.","Timmins, G. S.; Bradfute, S. B.; Deretic, V.; Kumar, S.; Clarke, E. C.; Ye, C.","https://www.biorxiv.org/content/10.1101/2020.08.11.245100v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.245100v1?rss=1,2020-08-11,2020-08-11,,False
95,"Pleiotropic effect of Lactoferrin in the prevention and treatment of COVID-19 infection: in vivo, in silico and in vitro preliminary evidences","The current treatments against SARS-CoV-2 have proved so far inadequate. A potent antiviral drug is yet to be discovered. Lactoferrin, a multifunctional glycoprotein, secreted by exocrine glands and neutrophils, possesses an antiviral activity extendable to SARS-Cov-2.

We performed a randomized, prospective, interventional study assessing the role of oral and intra-nasal lactoferrin to treat mild-to-moderate and asymptomatic COVID-19 patients to prevent disease evolution. Lactoferrin induced an early viral clearance and a fast clinical symptoms recovery in addition to a statistically significant reduction of D-Dimer, Interleukin-6 and ferritin blood levels. The antiviral activity of lactoferrin related to its binding to SARS-CoV-2 and cells and protein-protein docking methods, provided the direct recognition between lactoferrin and spike S, thus hindering the spike S attachment to the human ACE2 receptor and consequently virus entering into the cells.

Lactoferrin can be used as a safe and efficacious natural agent to prevent and treat COVID-19 infection.","Campione, E.; Lanna, C.; Cosio, T.; Rosa, L.; Conte, M. P.; Iacovelli, F.; Romeo, A.; Falconi, M.; Del Vecchio, C.; Franchin, E.; Lia, M. S.; Minieri, M.; Chiaramonte, C.; Ciotti, M.; Nuccetelli, M.; Terrinoni, A.; Iannuzzi, I.; Coppeda, L.; Magrini, A.; Moricca, N.; Sabatini, S.; Rosapepe, F.; Bartoletti, P. L.; Bernardini, S.; Andreoni, M.; Valenti, P.; Bianchi, L.","https://www.biorxiv.org/content/10.1101/2020.08.11.244996v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.244996v1?rss=1,2020-08-11,2020-08-11,,False
96,K18-hACE2 mice develop respiratory disease resembling severe COVID-19,"SARS-CoV-2 emerged in late 2019 and resulted in the ongoing COVID-19 pandemic. Several animal models have been rapidly developed that recapitulate the asymptomatic to moderate disease spectrum. Now, there is a direct need for additional small animal models to study the pathogenesis of severe COVID-19 and for fast-tracked medical countermeasure development. Here, we show that transgenic mice expressing the human SARS-CoV-2 receptor (angiotensin-converting enzyme 2 [hACE2]) under a cytokeratin 18 promoter (K18) are susceptible to SARS-CoV-2 and that infection resulted in a dose-dependent lethal disease course. After inoculation with either 104 TCID50 or 105 TCID50, the SARS-CoV-2 infection resulted in rapid weight loss in both groups and uniform lethality in the 105 TCID50 group. High levels of viral RNA shedding were observed from the upper and lower respiratory tract and intermittent shedding was observed from the intestinal tract. Inoculation with SARS-CoV-2 resulted in upper and lower respiratory tract infection with high infectious virus titers in nasal turbinates, trachea and lungs. The observed interstitial pneumonia and pulmonary pathology, with SARS-CoV-2 replication evident in pneumocytes, were similar to that reported in severe cases of COVID-19. SARS-CoV-2 infection resulted in macrophage and lymphocyte infiltration in the lungs and upregulation of Th1 and proinflammatory cytokines/chemokines. Extrapulmonary replication of SARS-CoV-2 was observed in the cerebral cortex and hippocampus of several animals at 7 DPI but not at 3 DPI. The rapid inflammatory response and observed pathology bears resemblance to COVID-19. Taken together, this suggests that this mouse model can be useful for studies of pathogenesis and medical countermeasure development.

Authors SummaryThe disease manifestation of COVID-19 in humans range from asymptomatic to severe. While several mild to moderate disease models have been developed, there is still a need for animal models that recapitulate the severe and fatal progression observed in a subset of patients. Here, we show that humanized transgenic mice developed dose-dependent disease when inoculated with SARS-CoV-2, the etiological agent of COVID-19. The mice developed upper and lower respiratory tract infection, with virus replication also in the brain after day 3 post inoculation. The pathological and immunological diseases manifestation observed in these mice bears resemblance to human COVID-19, suggesting increased usefulness of this model for elucidating COVID-19 pathogenesis further and testing of countermeasures, both of which are urgently needed.","Yinda, C. K.; Port, J. R.; Bushmaker, T. J.; Offei Owusu, I.; Avanzato, V. A.; Fischer, R. J.; Schulz, J. E.; Holbrook, M. G.; Hebner, M. J.; Rosenke, R.; Thomas, T.; Marzi, A.; Best, S. M.; de Wit, E.; Shaia, C.; van Doremalen, N.; Munster, V.","https://www.biorxiv.org/content/10.1101/2020.08.11.246314v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.246314v1?rss=1,2020-08-11,2020-08-11,,False
97,Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19,"The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 is a worldwide health emergency. The immense damage done to public health and economies has prompted a global race for cures and vaccines. In developing a COVID-19 vaccine, we applied technology previously used for MERS-CoV to produce a prefusion-stabilized SARS-CoV-2 spike protein by adding two proline substitutions at the top of the central helix (S-2P). To enhance immunogenicity and mitigate the potential vaccine-induced immunopathology, CpG 1018, a Th1-biasing synthetic toll-like receptor 9 (TLR9) agonist was selected as an adjuvant candidate. S-2P was combined with various adjuvants, including CpG 1018, and administered to mice to test its effectiveness in eliciting anti-SARS-CoV-2 neutralizing antibodies. S-2P in combination with CpG 1018 and aluminum hydroxide (alum) was found to be the most potent immunogen and induced high titer of spike-specific antibodies in sera of immunized mice. The neutralizing abilities in pseudotyped lentivirus reporter or live wild-type SARS-CoV-2 were measured with reciprocal inhibiting dilution (ID50) titers of 5120 and 2560, respectively. In addition, the antibodies elicited were able to cross-neutralize pseudovirus containing the spike protein of the D614G variant, indicating the potential for broad spectrum protection. A marked Th-1 dominant response was noted from cytokines secreted by splenocytes of mice immunized with CpG 1018 and alum. No vaccine-related serious adverse effects were found in the dose-ranging study in rats administered single- or two-dose regimens with up to 50 g of S-2P combined with CpG 1018 alone or CpG 1018 with alum. These data support continued development of CHO-derived S-2P formulated with CpG 1018/alum as a candidate vaccine to prevent COVID-19 disease.","Kuo, T.-Y.; Lin, M.-Y.; Coffman, R. L.; Campbell, J. D.; Traquina, P.; Lin, Y.-J.; Liu, L. T. C.; Cheng, J.; Wu, Y.-C.; Wu, C.-C.; Tang, W.-H.; Huang, C.-G.; Tsao, K.-C.; Shih, S.-R.; Chen, C.","https://www.biorxiv.org/content/10.1101/2020.08.11.245704v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.245704v1?rss=1,2020-08-11,2020-08-11,,False
98,Opposing activities of IFITM proteins in SARS-CoV-2 infection,"Interferon-induced transmembrane proteins (IFITMs) restrict infections by many viruses, but a subset of IFITMs enhance infections by specific coronaviruses through currently unknown mechanisms. Here we show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are generally restricted by expression of human IFITM1, IFITM2, and IFITM3, using both gain- and loss-of-function approaches. Mechanistically, restriction of SARS-CoV-2 occurred independently of IFITM3 S-palmitoylation sites, indicating a restrictive capacity that is distinct from reported inhibition of other viruses. In contrast, the IFITM3 amphipathic helix and its amphipathic properties were required for virus restriction. Mutation of residues within the human IFITM3 endocytosis-promoting Yxx{Phi} motif converted human IFITM3 into an enhancer of SARS-CoV-2 infection, and cell-to-cell fusion assays confirmed the ability of endocytic mutants to enhance Spike-mediated fusion with the plasma membrane. Overexpression of TMPRSS2, which reportedly increases plasma membrane fusion versus endosome fusion of SARS-CoV-2, attenuated IFITM3 restriction and converted amphipathic helix mutants into strong enhancers of infection. In sum, these data uncover new pro- and anti-viral mechanisms of IFITM3, with clear distinctions drawn between enhancement of viral infection at the plasma membrane and amphipathicity-based mechanisms used for endosomal virus restriction. Indeed, the net effect of IFITM3 on SARS-CoV-2 infections may be a result of these opposing activities, suggesting that shifts in the balance of these activities could be coopted by viruses to escape this important first line innate defense mechanism.","Shi, G.; Kenney, A. D.; Kudryashova, E.; Zhang, L.; Hall-Stoodley, L.; Robinson, R.; Kudryashov, D.; Compton, A. A. S.; Yount, J. S.","https://www.biorxiv.org/content/10.1101/2020.08.11.246678v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.246678v1?rss=1,2020-08-11,2020-08-11,,False
99,Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development,"The rapid spread of the COVID-19 demands immediate response from the scientific communities. Appropriate countermeasures mean thoughtful and educated choice of viral targets (epitopes). There are several articles that discuss such choices in the SARS-CoV-2 proteome, other focus on phylogenetic traits and history of the Coronaviridae genome/proteome. However none consider viral protein low complexity regions (LCRs). Recently we created the first methods that are able to compare such fragments. We show that five low complexity regions (LCRs) in three proteins (nsp3, S and N) encoded by the SARS-CoV-2 genome are highly similar to regions from human proteome. As many as 21 predicted T-cell epitopes and 27 predicted B-cell epitopes overlap with the five SARS-CoV-2 LCRs similar to human proteins. Interestingly, replication proteins encoded in the central part of viral RNA are devoid of LCRs. Similarity of SARS-CoV-2 LCRs to human proteins may have implications on the ability of the virus to counteract immune defenses. The vaccine targeted LCRs may potentially be ineffective or alternatively lead to autoimmune diseases development. These findings are crucial to the process of selection of new epitopes for drugs or vaccines which should omit such regions.

Author summaryThe outbreak of the COVID-19 disease affects humans all over the globe. More and more people get sick and many die because of the deadly SARS-CoV-2 virus. The whole machinery of this pathogen is enclosed in a short sequence of nucleotides, building blocks for both RNA and DNA strands. This RNA virus encodes less than 30 protein sequences that change the fate of our societies. Its proteins are composed of 20 amino acids (building bricks) that are usually used quite freely by proteins. However, there are fragments where only one or a few amino acids are used. We name those low complexity regions (LCRs). We invented the first programmes able to compare such LCRs. Using this new methodology we were able to show similarity of some viral proteins to human ones. This discovery has a serious implication when designing vaccines or drugs. It means that companies should not use these very LCRs as targets because it may trigger an autoimmune disease. On the other hand this specific similarity may suggest some kind of disguise of viral proteins into the machinery of human cells.","Gruca, A.; Ziemska-Legiecka, J.; Jarnot, P.; Sarnowska, E.; Sarnowski, T.; Grynberg, M.","https://www.biorxiv.org/content/10.1101/2020.08.11.245993v1?rss=1""",https://www.biorxiv.org/content/10.1101/2020.08.11.245993v1?rss=1,2020-08-11,2020-08-11,,False
